

FILE 'HOME' ENTERED AT 09:11:43 ON 10 NOV 2009

=> file reg  
CCST IN U.S. DOLLARS  
SINCE FILE  
ENTRY  
SESSION  
0.22  
0.22

FILE 'REGISTRY' ENTERED AT 09:11:53 ON 10 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITY data file

STRUCTURE FILE UPDATES: 8 NOV 2009 HIGHEST RN 1191799-54-8  
DICTIONARY FILE UPDATES: 8 NOV 2009 HIGHEST RN 1191799-54-8

For more information, visit [www.uspto.gov](http://www.uspto.gov) or call 1-800-786-9199.

TSCA INFORMATION NOW CURRENT THROUGH JUNE 26, 2009.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on how to use the REGISTRY, see the [REGISTRY User's Guide](#).

<http://www.zen-net/support/zenware/ntstates/properties.html>

-> Uploading C:\Program Files\STNEXP\Queries\10577334.str

```

chain nodes :
12 49
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18 19 20 21 22 23 24 25 26
27 28 29 30 31 32 33 34 35 36 41 42 43 44 45 46
ring/chain nodes :
10
chain bonds :
12-49
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18 18-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28
28-29
30-31 32-33
31-36 32-33 33-34 34-35 35-36 41-42 41-46 42-43 43-44 44-45 45-46
exact/norm bonds :
5-7 6-9 7-8 8-9 12-49
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24
20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30 31-32 31-36
32-33 33-34
34-35 35-36 41-42 41-46 42-43 43-44 44-45 45-46

```

G1: { \*1 }, { \*2 }, { \*3 }, { \*4 }, { \*5 }

```
Match level :  
1:Atom 10:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom  
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom  
31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom  
46:Atom 49:CLASS  
50:Atom
```

```
L1      STRUCTURE UPLOADED
=> d
L1 HAS NO ANSWERS
L1      STR
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.
```

```
> r 11 nsa sam
SAMPLE SEARCH INITIATED 09:12:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 22304 TO ITERATE
3 ANSWERS

9.0% PROCESSED      2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:    437137 TO 455023
PROJECTED ANSWERS:       322 TO 1016
```


```

L2           3 SEA SSS SAM 11

=> C READ

L2 3 ANSWERS  REGISTRY COPYRIGHT 2009 ACS ON STN
IN 1H-Benzimidazole-2,7-diamine, 1-phenyl-N7,N7-dipropyl-N2-(2,4,6-
      trimethylphenyl)-
MF C28 H14 N4


```



\*\* PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT \*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 1H-Benzimidazole-5-carboxamide, 6-(3,5-dimethyl-1-piperazinyl)-N-1H-  
C10-1H-indazol-6-yl-2-[{2-(trifluoromethyl)phenyl}amino]-  
MF C24 H27 F3 N8 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

-> **full**  
FULL SEARCH INITIATED 09:12:50 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 448427 TO ITERATE

100.0% PROCESSED 448427 ITERATIONS 586 ANSWERS  
SEARCH TIME: 00.00.08

>> file cap1  
COST IN U.S. DOLLARS  
SINCE FILE  
ENTRY  
186.36  
TOTAL  
SESSION  
186.58  
FULL ESTIMATED COST  
  
FILE 'CAP1.S' ENTERED AT 09:13:01 ON 10 NOV 2009  
ITS USE IS SUBJECT TO THE TERMS OF YOUR STM CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGERMITS" FOR DETAILS.  
C:\PROGRA~1\STMLIB\STM\STM.CAP1 (186.58)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Nov 2009 VOL 151 ISS 20  
FILE LAST UPDATED: 9 Nov 2009 (20091109/ED)

REVISED CLASS FIELDS (NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

Cplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/intropolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/Cplus family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

-> a 13  
L4 51 L3  
-> a 14 and (pd<20041027 or prd<20041027 or ad<20041027)  
25028355 PD<20041027  
4549516 PRD<20041027  
(PRD<20041027)  
5072655 AD<20041027  
(AD<20041027)

L5 36 L4 AND (PD<20041027 OR PRD<20041027 OR AD<20041027)

-> d 1-36 ibib hitlist

L5 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
DOCUMENT NUMBER: 2009:576501 CAPLUS <>LOGINDID:20091110>>  
DOCUMENT NUMBER: 150:515173

TITLE: Preparation of fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors

INVENTOR(S): Di Pietro, Lucian V.; Harmange, Jean-Christophe;  
Askev, Benny C. Jr.; Elbaum, Daniel; Germain, Julie;  
Habgood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.;  
Potashman, Michale; Van Der Plas, Simon

PATENT ASSIGNEE(S): Aqueon Inc., USA

SOURCE: U.S., 95pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO.     | KIND | DATE     | APPLICATION NO. | DATE        |
|----------------|------|----------|-----------------|-------------|
| US 7531553     | B2   | 20090512 | US 2004-004915  | 20040319 << |
| US 20040209892 | A1   | 20041021 |                 |             |
| AU 2004223827  | A1   | 20041007 | AU 2004-223827  | 20040322 << |
| AU 2004223827  | B2   | 20080306 |                 |             |
| CA 2518909     | A1   | 20041007 | CA 2004-2518909 | 20040322 << |
| WO 2004085425  | A1   | 20041007 | WO 2004-US8809  | 20040322 << |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, ER, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KS, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MW, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW, BM, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, HY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

EP 1638954 A1 20060329 EP 2004-758050 20040322 <<

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

JP 2006520805 T 20060914 JP 2006-507472 20040322 <<

MX 2005D10086 A 20060210 MZ 2005-1006 2005092 <<

PRIORITY APPLN. INFO.: US 2003-45691P P 20030321 <<

US 2004-004915 A 20040319 <<

WO 2004-US8809 A 20040322 <<

IT 1055984-37-6P 1055984-58-1P 1055984-62-7P

1055985-13-1P

RU: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)

RN 1055984-37-6 CAPLUS

CN 3-Pyridinecarboxamide, 4-[(2-((3,4-dichlorophenyl)amino)-1R-benzimidazol-5-yl)amino]-N-methyl- (CA INDEX NAME)


RN 1055984-58-1 CAPLUS

CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)-N6-(6,7-dimethoxy-4-quinolinyl)- (CA INDEX NAME)




RN 1055984-62-7 CAPLUS

CN 1H-Benzimidazole-2,6-diamine, N2-(4-cyclohexylphenyl)-N6-(2-(methylamino)-4-pyrimidinyl)- (CA INDEX NAME)



RN 1055985-13-1 CAPLUS  
 CN 1H-Benzimidazole-2,6-diamine, N2-(3-fluorophenyl)-N6-4-quinolinyl- (ICA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)  
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:341955 CAPLUS <<LOGINID:20091110>>  
 DOCUMENT NUMBER: 144:390938  
 TITLE: Aryl nitrogen-containing bicyclic compounds and their preparation, pharmaceutical compositions, and protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases  
 INVENTOR(S): Patel, Vinod P.; Kim, Joseph L.; Geuns-Meyer, Stephanie D.; Chaffee, Stuart C.; Cee, Victor J.; Hodous, Brian L.; Bellon, Steven; Harrange, Jean-Christophe; Olivieri, Philip R.; Thaman, Maya C.; Dimauro, Erin F.; Buchanan, John L.; McGowan, David C.; Albrecht, Brian K.; Doak, Holly L.; Hemis, Jean E.; White, Ryan; Martin, Matthew W.; Babgood, Gregory J.; Tempest, Paul A.; Masse, Craig E.; Buckner, William H.; Herberich, Bradley J.; Graceffo, Russell; Zhang, Dawei; Xu, Shimin; Sham, Kelvin; Rzana, Robert M.; Falsley, James Richard; Chakrabarti, Partha S.; Cao, Guo-Qiang; Tomlinson, Susan A.; Petrus, Liping H.; Smith, Adrian Leonard; Paras, Nick A.; Liu, Gang; Denehy, Francis F.; Tasker, Andrew; Reed, Anthony  
 PATENT ASSIGNEE(S): Amgen Inc., USA  
 SOURCE: PCT Int'l Appl., 876 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE        |
|--|------|----------|-----------------|-------------|
| WO 2006039718  | A2   | 20060413 | WO 2005-US35873 | 20051003 << |
| WO 2006039718  | A3   | 20060713 |                 |             |
| <b>W:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW<br><b>RE:</b> AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KP, MD, RU, TJ, UZ, ZA<br><b>US:</b> 2007030308 T 20070308 US 2005-240590 20050930 <<<br><b>AU:</b> 2005292152 A1 20060413 AU 2005-292152 20051003 <<<br><b>CA:</b> 2582023 A1 20060413 CA 2005-2582029 20051003 <<<br><b>EP:</b> 1836174 A2 20070526 EP 2005-818381 20051003 <<<br><b>R:</b> AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LY, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU<br><b>JP:</b> 2008515812 T 20080515 JP 2007-534914 20051003 <<<br><b>MX:</b> 2007003784 A 20070424 MX 2007-3784 20070329 <<<br><b>PRIORITY APPLN. INFO.:</b><br><b>OTHER SOURCE(S):</b> CASREACT 144:390936; MARPAT 144:390936<br><b>IT:</b> 882674-24-OP A1 20060413 IT 2005-292152 20051003 <<<br><b>RL:</b> PAF (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)<br><b>(Uses):</b> (drug candidate; preparation of aryl nitrogen-containing bicyclic compds.<br><b>and:</b> their protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases)<br><b>RN:</b> 882674-24-0 CAPLUS<br><b>CN:</b> 2-Quinazolinamine, N-methyl-6-[2-methyl-5-[(6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl)amino]phenyl]- (ICA INDEX NAME) |      |          |                 |             |



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
 (10 CITINGS)


15 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:696902 CAPLUS <<LOGINID:20091110>>

DOCUMENT NUMBER: 143:194003  
 TITLE: Preparation of aminobenzazoles and analogs as P2Y1 receptor inhibitors for treating thromboembolic disorders  
 INVENTOR(S): Herpin, Timothy F.; Morton, George C.; Rehfuss, Robert P.; Lawrence, R. Michael; Foss, Michael A.; Roberge, Jacques Y.; Gungor, Timur  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 256 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE            |
|---|------|----------|-----------------|-----------------|
| WO 2005070920   | A1   | 20050804 | WO 2005-US1705  | 20050120 <--    |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |      |          |                 |                 |
| RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SI, TZ, UW, ZA, ZM, ZW  |      |          |                 |                 |
| AZ, BY, KG, KZ, MD, RO, TZ, UG, US, UZ, VC, VN, ZA, ZM, ZW  |      |          |                 |                 |
| EE, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, RO, SE, SI, SK, TR, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU  |      |          |                 |                 |
| JP 20050218809  | T    | 20070712 | JP 2006-551237  | 20050120 <--    |
| US 7470712  | B2   | 20081230 | .               |                 |
| EP 1706398  | A1   | 20061004 | EP 2005-711563  | 20050120 <--    |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU   |      |          |                 |                 |
| JP 20050218809  | T    | 20070712 | JP 2006-551237  | 20050120 <--    |
| NO 2005003191   | A    | 20061016 | NO 2006-3191    | 20060710 <--    |
| US 200802275090   | A1   | 20081106 | US 2008-104732  | 20080417 <--    |
| PRIORITY APPLN. INFO.:  |      |          | US 2004-537869P | P 2004121 <--   |
|   |      |          | US 2004-638167P | P 20041222      |
|   |      |          | US 2005-3RH62   | A3 20050119 <-- |
|   |      |          | WO 2005-US1705  | W 20050120 <--  |

OTHER SOURCE(S): CASREACT 143:194003; MARPAT 143:194003  
 IT 861670-3-IP 861670-94-2P,  
 N-[2-[(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-4-nitro-1H-benzod[d]imidazol-2-amine 861670-95-4P,  
 N-[2-(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-5-nitro-1H-benzod[d]imidazol-2-amine 861671-18-3P,  
 N-[2-[(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-5-(1H-imidazol-1-yl)-7-methyl-1H-benzod[d]imidazol-2-amine 861671-20-7P,  
 4-Nitro-N-[2-[(3-(trifluoromethyl)phenoxy)pyridin-3-yl]-1H-benzod[d]imidazol-2-amine 861671-22-9P, 5-Nitro-N-[2-[(3-(trifluoromethyl)phenoxy)pyridin-3-yl]-1H-benzod[d]imidazol-2-amine 861671-92-3P, N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-5-methyl-1H-benzod[d]imidazole-2,4-diamine 861671-96-7P,  
 N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-6-(morpholino)-1H-benzod[d]imidazol-2-amine 861671-98-9P,  
 N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-N',N'-dimethyl-1H-benzod[d]imidazole-2,5-diamine 861674-50-2P  
 RL: PA (Pharmacological activity); SPA (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)  
 (drug candidate; preparation of aminobenzazoles and analogs as P2Y1 receptor inhibitors for treating thromboembolic disorders)  
 RN 861670-93-1 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-[2-[(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-S-(1H-imidazol-1-yl)-7-methyl- (CA INDEX NAME)




RN 861670-94-2 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-[2-[(1,1-dimethylethyl)phenoxy]-6-methoxy-3-pyridinyl]-7-nitro- (CA INDEX NAME)




RN 861670-96-4 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-[2-[(1,1-dimethylethyl)phenoxy]-6-methoxy-3-pyridinyl]-6-nitro- (CA INDEX NAME)




RN 861671-18-3 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-[2-(2-(1,1-dimethylethyl)phenoxy)-6-methoxy-3-pyridinyl]-5-(1H-imidazol-1-yl)-7-methyl- (CA INDEX NAME)




RN 861671-20-7 CAPLUS  
CN 1H-Benzimidazol-2-amine, 7-nitro-N-[2-(3-(trifluoromethyl)phenoxy)-3-pyridinyl]- (CA INDEX NAME)




RN 861671-22-9 CAPLUS  
CN 1H-Benzimidazol-2-amine, 6-nitro-N-[2-(3-(trifluoromethyl)phenoxy)-3-pyridinyl]- (CA INDEX NAME)




RN 861671-92-3 CAPLUS  
CN 1H-Benzimidazol-2,7-diamine, N-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-6-methyl- (CA INDEX NAME)



RN 861671-96-7 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-[2-(2-(1,1-dimethylethyl)phenoxy)-3-pyridinyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 861671-98-9 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-N6,N6-dimethyl- (CA INDEX NAME)



RN 861674-50-2 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-[2-(2-(1,1-dimethylethyl)phenoxy)-3-pyridinyl]-

6-methyl-7-nitro- (CA INDEX NAME)




IT 1026562-20-BP

RL: SPN (Synthetic preparation); PREP (Preparation);  
(preparation of 6-aminobenzodiazoles and analogs as P2Y1 receptor inhibitors for  
treating thromboembolic disorders)

RN 1026562-20-8 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-(2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-  
7-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(6 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 4 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:429393 CAPLUS <>LOGINID::20091110>>

DOCUMENT NUMBER: 142:482043

TITLE: Preparation of nitrogen-containing fused heterocyclic  
compounds like benzimidazoles and benzothiazoles as  
CRF receptor antagonists

INVENTOR(S): Cho, Suk Young; Corriveau, Christopher Peter;  
Cho, Suk Young; Turner, Timothy Mark; Pratt, Scott

Alam, Aso; Kazuyoshi; Kori, Maakuni; Gyoten, Michiyo

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int'l. Appl., 273 pp.

DOCUMENT TYPE: CODEN: PIIXD2

Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE        |
|---------------|------|----------|-----------------|-------------|
| WO 2005044793 | A2   | 20050519 | WO 2004-US35648 | 20041027 << |
| WO 2005044793 | A3   | 20060330 |                 |             |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NT,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: RW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE,  
SN, TD, TG

CA 2543707 A1 2004-2543707 20041027 <<

EP 1677791 A2 20060712 EP 2004-810065 20041027 <<

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007510646 T 20070426 JP 2006-538217 20041027 <<

US 20070135452 A1 20070614 US 2006-577334 20060428

PRIORITY APPLN. INFO.: US 2003-516164P P 20031031 <<

US 2004-560518P P 20040408 <<

WO 2004-US35648 W 20041027

OTHER SOURCE(S): CASREACT 142:482043; MARPAT 142:482043


IT 851886-96-9P, N'-Benzyl-N-methyl-1-methyl-N'-propyl-1H-  
benzimidazole-2,7-diamine 851888-22-7P,  
4-[(2-(4-Bromo-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-  
yl)(isopropyl)amino]butanoic acid 851888-23-8P, Methyl  
4-[(2-(4-bromo-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-  
yl)(isopropyl)amino]butanoic acid 851889-51-2P, Ethyl  
4-[(2-(4-methoxyphenyl)glycinato)-1-methyl-1H-benzimidazol-7-  
yl-N-(4-methoxyphenyl)glycinato 851888-76-1P,  
5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-  
yl)amino]phenoxylbutanenitrile 851889-08-2P,  
4-[(5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-  
yl)amino]phenoxylbutyryl acid 851889-02-6P, N-[2-(3-Bromopropoxy)-4-chlorophenyl]-1-methyl-N',N'-  
dipropyl-1H-benzimidazole-2,7-diamine 851889-03-7P,  
4-(5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-  
yl)amino]phenoxylbutanenitrile 851889-08-2P,  
4-[(5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-  
yl)amino]phenoxylbutyryl acid

RL: PAK (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of nitrogen-containing fused heterocyclic  
compds.


like benzimidazoles and benzothiazoles as CRF receptor antagonists with  
therapeutic potential)

RN 851886-96-9 CAPLUS


CN 1H-Benzimidazole-2,7-diamino, 1-methyl-N-(phenylmethyl)-N7-propyl-N2-  
(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-22-7 CAPLUS  
 CN Butanoic acid, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]- (CA INDEX NAME)




RN 851888-23-8 CAPLUS  
 CN Butanoic acid, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-, methyl ester (CA INDEX NAME)




RN 851888-51-2 CAPLUS  
 CN Glycine, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 851888-76-1 CAPLUS  
 CN Phenol, 5-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 851889-02-6 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamino, N2-(2-(3-bromopropoxy)-4-chlorophenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)



RN 851889-03-7 CAPLUS  
 CN Butanenitrile, 4-[(5-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenoxy)- (CA INDEX NAME)



RN 851889-08-2 CAPLUS  
 CN Butanoic acid, 4-(5-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenoxy)- (CA INDEX NAME)



IT 851886-84-5P, N-Mesityl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-87-8P, N-Mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-88-9P, N-Mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-89-0P, N-Mesityl-1-phenyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-90-3P, 1-Ethyl-N-mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-91-4P, N'-Cyclopropylmethyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851886-99-2P, 1-Methyl-N-phenyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-03-1P, Methyl 4-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]-3-methylbenzoate trifluoroacetate 851887-05-3P, N-(2,6-Dimethylpyridin-3-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-07-5P, N-(4-tert-Butyl-2,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-09-7P, N-(2,4-Dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-11-1P, N-(1-Ethyl-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-13-3P, N-(4-Dimethylamino)-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-15-5P, 1-Methyl-N-(4-methyl-5-nitropyridin-2-yl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-17-7P, N-(2,4-Dichlorophenoxy)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-19-9P, N-(2-Chloro-4,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-21-3P, N-(2-Bromo-4-isopropylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-23-5P, 1-Methyl-N',N'-dipropyl-N-(2,4,6-trichlorophenyl)-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-27-9P, N-(4,5-Dimethoxy-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-29-1P, N-(2,6-Dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-31-5P, N-(4-Dichloro-6-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]-3-methylphenyl)trifluoroacetate 851887-33-7P, N-(3,5-Dichloropyridin-4-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-35-9P, N-(3-Bromo-5-methylpyridin-2-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-37-1P, N-(3,5-Dimethoxyphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-


diamine trifluoroacetate 851887-39-3P, 1-Methyl-N-[2-methyl-4-(trifluoromethyl)phenyl]-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-41-7P, N-(2,4-Dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-42-8P, N',N'-Dibutyl-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-43-9P, N',N'-Bis(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-44-0P, N-Mesityl-1-methyl-1-(piperidin-1-yl)-1H-benzimidazol-2-amine 851887-45-1P, N'-Butyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-46-2P, N-Mesityl-1-methyl-N'-(2-methoxyethyl)-N'-propyl-1H-benzimidazole-2,7-diamine 851887-47-3P, N'-Isobutyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-55-3P, 5-Fluoro-N-mesityl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-57-5P, N',N'-Dibutyl-5-fluoro-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-58-6P, N'-Bis(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-59-7P, N'-Bis(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-63-3P, N-Mesityl-1-methyl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-64-4P, N'-Isopropyl-1-methyl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-65-5P, N-Mesityl-1-methyl-N'-(1-propylbutyl)-1H-benzimidazole-2,7-diamine 851887-66-6P, N'-Benzyl-N-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-67-7P, N-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-68-8P, N-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-69-9P, N-(Cyclopropylmethyl)-N'-N-(4-Chlorobenzyl)-N'- (cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-70-2P, N-(Cyclopropylmethyl)-N'-N-(2-(methylamino)-1-methyl-1H-benzimidazol-7-yl)-N-(4-tert-Butylcyclopropyl)-N'- (cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-73-5P, N'-Benzyl-N-(cyclopropylmethyl)-N-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-74-6P, N'-Benzyl-N-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-75-7P, N'-Benzyl-N-(cyclopropylmethyl)-N-(4-fluorobenzyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-76-8P, 4-[(Cyclopropylmethyl)-2-(methylamino)-1-methyl-1H-benzimidazol-7-yl]amino)benzonitrile 851887-77-9P, N'-Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(pyridin-2-ylmethyl)-1H-benzimidazole-2,7-diamine 851887-78-0P, N'-[2-(Benzoyloxyethyl)-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine] 851887-79-1P, 2-(Cyclopropylmethyl)-2-(methylamino)-1-methyl-1H-benzimidazol-7-ylamino)benzyl 851887-80-4P, N-(4-Bromo-2,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-81-5P, N-(4-Methoxy-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-82-6P, N-(2,6-Dimethoxy-4-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-83-7P, N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-84-8P, N-(2,6-Dichloropyridin-3-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-85-9P, 4-[(7-(Dipropylamino)-1-methyl-1H-

benzimidazol-2-yl)amino)-3-ethylbenzonitrile 851887-86-0P, N-(2,4-Dimethoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-87-1P, N-(2,4-Dichloro-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-88-2P, N-(2-Chloro-6-(trifluoromethyl)pyridin-3-yl)-1-ethyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-89-3P, N-(2-Chloro-4-(trifluoromethyl)pyridin-3-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-90-6P, N-(2-Bromo-4-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-91-7P, N-(4-Chloro-2-methoxy-5-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-92-8P, N-(4-Bromo-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-93-9P, N-(2-Chloro-2-methylphenyl)-N-(2,4-dimethylbenzyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-94-0P, N-(4-Bromo-2-ethylphenyl)-N',N'-dibutyl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-95-1P, N-(4-Chloro-2-isopropyl-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-96-2P, N-(4-Chloro-2-(4-dimethoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-97-3P, N-(2-Chloro-4-(4-methoxy-6-methylphenyl)-N',N'-dibutyl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-99-5P, N-Mesityl-1-(2-methoxyethyl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-00-1P, N-Mesityl-N',N'-dipropyl-1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2,7-diamine 851888-01-2P, Z-[7-(Dipropylamino)-2-(methylaminol-1H-benzimidazol-1-yl)ethanol 851888-02-3P, N',N'-Bis(cyclopropylmethyl)-1-methyl-N-(2,4,6-trimethylpyridin-3-yl)-1H-benzimidazole-2,7-diamine 851888-03-4P, 1-Acetyl-N-mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-04-5P, N',N'-Dibutyl-N-mesityl-1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2,7-diamine 851888-05-6P, N',N'-Bis(cyclopropylmethyl)-N-mesityl-1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2,7-diamine 851888-06-7P, 4-Bromo-2-(methylaminol-1H-benzimidazol-1-yl)ethanol-2,7-diamine 851888-12-5P, N-(2,4,6-Trimethylpyridin-3-yl)-1-methyl-N',N'-di(2-methoxyethyl)-1H-benzimidazole-2,7-diamine hydrochloride 851888-18-1P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-bis(2-methoxyethyl)-1H-benzimidazole-2,7-diamine 851888-20-5P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-(2-methoxyethyl)-N'-methyl-1-methoxybenzimidazole-2,7-diamine 851888-21-6P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-(2-methoxyethyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-24-9P, 4-[(2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(isopropyl)amino]-N-methylbutanamide 851888-25-0P, 4-[(2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(isopropyl)amino]-N,N-dimethylbutanamide 851888-26-1P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-N'-[(4-oxo-4-(pyrrolidin-1-yl)butyl)-1H-benzimidazole-2,7-diamine 851888-27-2P, 4-[(2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(isopropyl)amino]-N,N-dimethylbutanamide 851888-28-3P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-29-4P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-30-7P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-31-8P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-N'-[(4-(4-methylpiperazin-1-yl)-4-oxobutyl)-1H-benzimidazole-2,7-


diamine 851888-32-9P, N'-[2-[(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-1H-benzimidazol-7-yl]-N'-isopropylglycinamide 851888-33-0P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-[(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851888-35-2P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-[(2-(dimethylaminoethyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine Hydrochloride 851888-37-4P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-[(4-chlorophenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine Hydrochloride 851888-43-2P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-[(4-chlorophenyl)-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851888-44-3P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-[(4-chlorophenyl)-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851888-45-4P, Ethyl N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)glycinamide hydrochloride 851888-46-5P, N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)-N,N-dimethylglycinamide hydrochloride 851888-47-6P, N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)-N-(4-chlorophenyl)-N'-[(4-chlorophenyl)-1-methyl-1H-benzimidazole-2,7-diamine dihydrochloride 851888-48-7P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-[(4-chlorophenyl)-1-methyl-N'-[(tetrahydrofuran-3-yl)methyl]-1H-benzimidazole-2,7-diamine 851888-49-8P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-isopropyl-1-(4-methoxyphenyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-50-1P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-[(2-methoxyethyl)-N-(4-methoxyphenyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-52-3P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-[(4-methoxyphenyl)-1-methyl-1H-benzimidazol-7-yl]-N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)acetamide Hydrochloride 851888-55-7P, N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)acetamide 851888-56-8P, N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)acetamide 851888-57-9P, N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)acetamide 851888-58-0P, N-[2-[(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)acetamide 851888-59-1P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-ethyl-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851888-61-4P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-64-7P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N',N'-dibutyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-65-8P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-66-9P, Methyl 4-[(2-[(4-methylpiperazin-1-yl)-4-oxobutyl)-1H-benzimidazol-7-yl](isopropyl)amino]-1-methyl-1H-benzimidazol-7-yl-1-methylbutanate 851888-67-0P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N',N'-diethyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-68-1P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-69-2P, N-(3,4-Dichloro-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-70-5P,

N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-N'-methyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-71-6P,  
 N'-Ethyl-N'-isopropyl-1-methyl-N-(2,4,6-trimethoxyphenyl)-1H-benzimidazole-2,7-diamine 851888-72-7P,  
 N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-ethyl-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-73-8P,  
 N-(4-Chloro-2-methoxy-6-methylphenyl)-N',N'-diethyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-74-9P,  
 N-(4-Chloro-2,6-dimethoxyphenyl)-N',N'-diethyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-75-0P, N-(4-Chloro-2,6-dimethoxyphenyl)-N'-ethyl-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-77-2P  
 , (5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenyl)methanol 851888-78-3P,  
 N-(4-Chloro-2-methoxyphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-79-4P, N-(2-Bromo-4-chlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-81-8P,  
 5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]benzonitrile 851888-82-9P,  
 N-(4-Chloro-2-(methoxymethyl)phenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-83-0P,  
 N,N'-Bis[2-(benzoyloxy)ethyl]-1-methyl-N-(2,4,6-trimethylpyridin-3-yl)-1H-benzimidazole-2,7-diamine 851888-84-1P,  
 N-(4-Chloro-2-ethoxyphenyl)-3-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-85-2P, N-(4-Chloro-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-piperidinyl)-1-methyl-1H-benzimidazol-2-amine 851888-86-3P,  
 N-(4-Chloro-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-piperidinyl)-1-methyl-1H-benzimidazol-2-amine 851888-87-4P,  
 N-(4-Chloro-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methylpiperidin-1-yl)-1H-benzimidazol-2-amine 851888-88-5P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-pyrrolidinyl)-1-methyl-1H-benzimidazol-2-amine 851888-89-6P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1H-pyrrolidin-1-yl)-1H-benzimidazol-2-amine 851888-90-7P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-7-(3-ethyl-4-morpholinyl)-1-methyl-1H-benzimidazol-2-amine 851888-91-8P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-propyl-1-piperidinyl)-1H-benzimidazol-2-amine 851888-92-9P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methoxymethyl-1-piperidinyl)-1H-benzimidazol-2-amine 851888-93-0P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methoxymethyl-1-piperidinyl)-1H-benzimidazol-2-amine 851888-94-1P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methoxymethyl-1-piperidinyl)-1H-benzimidazol-2-amine 851888-95-2P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methoxymethyl-1-piperidinyl)-1H-benzimidazol-2-amine 851888-96-3P, Methyl 4-[2-(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-2-yl]piperidine-2-carboxylate 851888-97-4P,  
 N-(2-(2-Bromoethoxy)-4-chlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-98-5P,  
 [5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenyl]acetonitrile 851888-00-6P,  
 N-(2-(4-Bromobutoxy)-4-chlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-01-7P,  
 5-[5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenyl]pentanenitrile 851888-09-3P,  
 4-[5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenyl]-N-methylbutanamide Hydrochloride 851888-10-6P  
 , 4-[5-Chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenyl]-N-methylbutanamide 851888-19-5P,  
 N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-propyl-1-methyl-N-(2-methoxymethylphenyl)-1H-benzimidazole-2,7-diamine 851888-22-0P, 4-[2-(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-2-yl]piperidine-2-carboxylate 851888-28-6P, 4-[(2-[(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-2-yl)amino]benzonitrile 851888-30-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BICL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of nitrogen-containing fused heterocyclic compds.  
 like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential)  
 RN 851886-04-5 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851886-87-8 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851886-88-9 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-(1-methylethyl)-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851886-89-0 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-phenyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-90-3 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-ethyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851886-91-4 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-99-2 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-phenyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851886-98-1  
 CMF C20 H26 N4




CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 851887-03-1 CAPLUS  
 CN Benzoic acid, 4-[(7-(dipropylamino)-1H-benzimidazol-2-ylamino)-3-methyl-, methyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-02-0  
 CMF C23 H30 N4 O2



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 851887-05-3 CAPLUS  
1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethoxy-3-pyridinyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-04-2  
CMF C21 H29 N5 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-07-5 CAPLUS  
1H-Benzimidazole-2,7-diamine, N2-[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-06-4  
CMF C26 H38 N4



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 851887-09-7 CAPLUS

1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-09-6  
CMF C22 H30 N4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-11-1 CAPLUS  
1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-ethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 851887-10-0  
CMF C22 H29 Br N4



CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-13-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[4-(diethylamino)-2-methylphenyl]-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)  
CM 1  
CRN 851887-12-2  
CMF C25 H37 N5




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-15-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(4-methyl-5-nitro-2-pyridinyl)-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1  
CRN 851887-14-4  
CMF C20 H26 N6 O2




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-17-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dichlorophenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1  
CRN 851887-16-6  
CMF C20 H24 Cl2 N4




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-19-9 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N<sup>2</sup>-(2-chloro-4,6-dimethylphenyl)-1-methyl-N<sup>7</sup>,N<sup>7</sup>-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-18-8  
 CMF C22 H29 Cl1 N4



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 851887-21-3 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N<sup>2</sup>-(2-bromo-4-(1-methylethyl)phenyl)-1-methyl-N<sup>7</sup>,N<sup>7</sup>-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-20-2  
 CMF C23 H31 Br N4



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 851887-23-5 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N<sup>7</sup>,N<sup>7</sup>-dipropyl-N<sup>2</sup>-(2,4,6-trichlorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-22-4  
 CMF C20 H23 Cl13 N4



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 851887-27-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4,5-dimethoxy-2-methylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-28-0  
CMF C23 H32 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 C2



RN 851887-29-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-28-0  
CMF C22 H30 N4



CM 2


CRN 76-05-1  
CMF C2 H F3 C2



RN 851887-31-5 CAPLUS  
CN Phenol, 2,4-dichloro-6-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]-3-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-30-4  
CMF C21 H26 C12 N4 O



CM 2


CRN 76-05-1  
CMF C2 H F3 C2



RN 851887-33-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(3,5-dichloro-4-pyridinyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-32-6  
CMF C19 H23 C12 N5




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-35-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(3-bromo-5-methyl-2-pyridinyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1  
CRN 851887-34-8  
CMF C20 H26 Br N5




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-37-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(3,5-dimethoxyphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1  
CRN 851887-36-0  
CMF C22 H30 N4 O2




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-39-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-[2-methyl-4-(trifluoromethoxy)phenyl]-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1  
CRN 851887-38-2  
CMF C22 H27 F3 N4 O



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-41-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethoxyphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-40-6  
CMF C22 H30 N4 O2




CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 851887-42-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-43-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-44-0 CAPLUS  
CN 1H-Benzimidazol-2-amine, 1-methyl-7-(1-piperidinyl)-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851887-45-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-butyl-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-46-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(2-methoxyethyl)-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




MeO-CH<sub>2</sub>-CH<sub>2</sub>


RN 851887-47-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(2-methylpropyl)-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851887-55-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 5-fluoro-1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-57-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-diethyl-5-fluoro-1-methyl-N2-(2,4,6-trimethylphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-58-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-5-fluoro-1-methyl-N2-(2,4,6-trimethylphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 851887-59-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-butyl-N7-(4-methoxyphenyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-63-3 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N7,1-dimethyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-64-4 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(1-methylethyl)-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-65-5 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(1-propylbutyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-66-6 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(phenylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-67-7 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N7-[(4-chlorophenyl)methyl]-N7-(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-68-8 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(4-methoxyphenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-69-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(3-pyridinylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-70-2 CAPLUS  
CN Acetamido, N-(cyclopropylmethyl)-N-[1-methyl-2-(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl- (CA INDEX NAME)




RN 851887-71-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(4-(1,1-dimethylethyl)phenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851887-72-4 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(4-methylphenyl)methyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-73-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(4-pyridinylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-74-6 CAPLUS


RN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[(4-(trifluoromethyl)phenyl)methyl]-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-75-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(4-fluorophenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-76-8 CAPLUS  
CN Benzonitrile, 4-[(cyclopropylmethyl)[1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl]amino]methyl- (CA INDEX NAME)




RN 851887-77-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(2-pyridinylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-78-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(2-(phenylmethoxy)ethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-79-1 CAPLUS  
CN Ethanol, 2-[(cyclopropylmethyl)(1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl)amino]- (CA INDEX NAME)




RN 851887-80-4 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2,6-dimethylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-81-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-methoxy-2-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-82-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethoxy-4-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-83-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-84-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dichloro-3-pyridinyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)



RN 851887-85-9 CAPLUS  
CN Benzonitrile, 4-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-ethyl- (CA INDEX NAME)




RN 851887-86-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-87-1 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dichloro-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-88-2 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-[2-chloro-6-(trifluoromethyl)-3-pyridinyl]-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-89-3 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-[2-chloro-4-(trifluoromethyl)phenyl]-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-90-6 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-91-7 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-5-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 851887-92-8 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-93-9 CAPLUS


RN 851887-94-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-ethylphenyl)-N7,N7-dibutyl-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




RN 851887-94-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-ethylphenyl)-N7,N7-dibutyl-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




RN 851887-95-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[4-chloro-2-methyl-6-(1-methylcyclohexyl)phenyl]-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




RN 851887-96-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2,N7-dibutyl-N2-(2,4-dimethoxy-6-methylphenyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




RN 851887-97-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-methoxy-6-methylphenyl)-N7,N7-dibutyl-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




RN 851887-99-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-(2-methoxyethyl)-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-00-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dipropyl-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-01-2 CAPLUS  
CN 1H-Benzimidazole-1-ethanol, 7-(dipropylamino)-2-[ (2,4,6-trimethylphenyl)amino]- (CA INDEX NAME)




RN 851888-02-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethyl-3-pyridinyl)- (CA INDEX NAME)




RN 851888-03-4 CAPLUS  
CN Echanone, 1-[7-(dipropylamino)-2-((2,4,6-trimethylphenyl)amino)-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 851888-04-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-05-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851888-06-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 4-bromo-1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-12-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(2-methoxymethyl)-1-methyl-N2-(2,4,6-trimethyl-3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 851888-18-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,N7-bis(2-methoxymethyl)-1-methyl- (CA INDEX NAME)




RN 851888-20-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-(2-methoxymethyl)-N7,1-dimethyl-, (CA INDEX NAME)




RN 851888-21-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-(2-methoxymethyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-24-9 CAPLUS  
CN Butanamide, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-N-methyl- (CA INDEX NAME)




RN 851888-25-C CAPLUS  
CN Butanamide, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-N,N-dimethyl-, (CA INDEX NAME)




RN 851888-26-1 CAPLUS  
 CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 851888-27-2 CAPLUS  
 CN Butanamide, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-N,N-diethyl- (CA INDEX NAME)




RN 851888-28-3 CAPLUS  
 CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-1-(4-morpholinyl)- (CA INDEX NAME)




RN 851888-29-4 CAPLUS  
 CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 851888-30-7 CAPLUS  
 CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-1-(4-thiomorpholinyl)- (CA INDEX NAME)




RN 851888-31-8 CAPLUS  
 CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(i-methylethyl)amino]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 851888-32-9 CAPLUS  
 CN Acetamide, 2-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(i-methylethyl)amino]- (CA INDEX NAME)




RN 851888-33-0 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2-aminoethyl)-N7-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(i-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 851888-35-2 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-(2-(dimethylaminolethyl)-1-methyl-N7-(i-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-37-4 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-1-methyl-N7-(i-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-43-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-N7-(2,2-dimethylpropyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-44-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-N7-(2-methoxyethyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-45-4 CAPLUS  
CN Glycine, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 851888-46-5 CAPLUS  
CN Acetamide, 2-[(2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(4-chlorophenyl)amino]-N,N-dimethyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-47-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-N7-[2-(dimethylamino)ethyl]-1-methyl-, hydrochloride (1:2)  
(CA INDEX NAME)




●2 HCl


RN 851888-48-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-1-methyl-N7-[1-(tetrahydro-3-furanyl)methyl]-  
(CA INDEX NAME)



RN 851888-49-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-methoxyphenyl)-1-methyl-N7-(1-methylethyl)-  
(CA INDEX NAME)




RN 851888-50-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-N7-(4-methoxyphenyl)-1-methyl-  
(CA INDEX NAME)




RN 851888-52-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-


methoxyphenyl)-1-methyl-N7-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 851888-53-4 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-N7-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 851888-54-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-1-methyl-N7-(5-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 851888-55-6 CAPLUS  
CN Acetamide, 2-[(2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(4-methoxyphenyl)amino]-N,N-diethyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 851888-56-7 CAPLUS  
CN Acetamide, N-[7-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 851888-58-9 CAPLUS  
CN Acetamide, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 851888-59-0 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 851888-61-4 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 851888-62-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851888-63-6 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2,6-diethylphenyl)-1-methyl-N7,N7-diproptyl- (CA INDEX NAME)




RN 851888-64-7 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,N7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-65-8 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-1-methyl-N7,N7-diproptyl- (CA INDEX NAME)







RN 851888-66-9 CAPLUS  
CN Butanoic acid, 4-[(cyclopropylmethyl)(1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl)amino]-, methyl ester (CA INDEX NAME)




RN 851888-67-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,N7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-68-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-69-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(3,4-dichloro-2-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-70-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,1-diethyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-71-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-ethyl-1-methyl-N7-(1-methylethyl)-N2-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 851888-72-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-73-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7,N7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-74-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-N7,N7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-75-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-77-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 851888-78-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxyphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-79-4 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-chlorophenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-81-8 CAPLUS  
CN Benzonitrile, 5-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 851888-82-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[4-chloro-2-(methoxymethyl)phenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-83-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7,N7-bis[2-(phenyimethoxy)ethyl]-N2-(2,4,6-trimethyl-3-pyridinyl)- (CA INDEX NAME)




RN 851888-84-1 CAPLUS  
CN 1H-Benzimidazole-2,4-diamine, N2-(4-chloro-2-ethoxyphenyl)-2,3-dihydro-1-methyl-N4,N4-dipropyl- (CA INDEX NAME)




RN 851888-85-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(2,3,4,5,6-pentamethylphenyl)-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-86-3 CAPLUS  
CN 1H-Benzimidazole-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-piperidinyl)-1-methyl- (CA INDEX NAME)




RN 851888-89-6 CAPLUS  
CN 1H-Benzimidazole-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 851888-90-9 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-pyrrolidinyl)-1-methyl- (CA INDEX NAME)




RN 851888-91-0 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1-pyrrolidinyl)- (CA INDEX NAME)




RN 851888-92-1 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(3-ethyl-4-morpholinyl)-1-methyl- (CA INDEX NAME)




RN 851888-93-2 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-propyl-1-piperidinyl)- (CA INDEX NAME)




RN 851888-94-3 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(2-methoxymethyl)-1-piperidinyl-1-methyl- (CA INDEX NAME)




RN 851888-95-4 CAPLUS  
CN 2,5-Pyridinediamine, N5-[7-(2-ethyl-1-piperidinyl)-1-methyl-1H-benzimidazol-2-yl]-N2,N2,4-trimethyl- (CA INDEX NAME)




RN 851888-96-5 CAPLUS  
CN 2-Piperidinocarboxylic acid, 1-[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-, methyl ester (CA INDEX NAME)




RN 851889-04-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamino, N2-[2-(2-bromoethoxy)-4-chlorophenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851889-05-9 CAPLUS  
CN Acetonitrile, 2-[5-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenoxy]- (CA INDEX NAME)




RN 851889-06-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamino, N2-[2-(4-bromobutoxy)-4-chlorophenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)



RN 851889-07-1 CAPLUS  
CN Pentanenitrile, 5-[5-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenoxy]- (CA INDEX NAME)




RN 851889-09-3 CAPLUS  
CN Butanamide, 4-(5-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenoxy)-N-methyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 851889-10-6 CAPLUS  
CN Butanamide, 4-[5-chloro-2-[(7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl)amino]phenoxy)-N,N-dimethyl- (CA INDEX NAME)




RN 851889-19-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamino, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-[2-(methylsulfonyl)phenyl]-N7-propyl- (CA INDEX NAME)



RN 851889-22-0 CAPLUS  
Benzonitrile, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]- (CA INDEX NAME)




RN 851889-28-6 CAPLUS  
Benzonitrile, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)(1-methylethyl)amino]-2-methoxy- (CA INDEX NAME)




IT 851889-19-2, N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-2,7-diamino 851889-34-1, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-


benzimidazole-2,7-diamine 851889-36-3, N'-(2-Aminoethyl)-N-(4-bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine  
RL RCT (Reactant); RACT (Reagent or reagent)  
(preparation of nitrogen-containing fused heterocyclic compds. like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential)  
RN 851889-19-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl- (CA INDEX NAME)



RN 851889-34-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851889-36-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(2-aminoethyl)-N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-2,7-diamine, N7-(2-aminoethyl)-N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-2,7-diamine (CA INDEX NAME)




IT 851886-86-7P, N-Methyl-1-methyl-1H-benzimidazole-2,7-diamine  
851886-97-0P, N-Methyl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)  
(preparation of nitrogen-containing fused heterocyclic compds. like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential)

RN 051886-86-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 051886-97-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



05.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
(6 CITINGS)  
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 5 OF 36 CAPLUS COPYRIGHT 2009 ACS OR STN  
ACCESSION NUMBER: 2005:409508 CAPLUS <>LOGINID:20091110>>  
DOCUMENT NUMBER: 142:463726  
TITLE: Preparation of benzimidazolyls as Tie-2 tyrosine  
kinase inhibitors for the treatment of tumors  
INVENTOR(S): Stachle, Wolfgang; Buchstaller, Hans-Peter; Jonczyk,  
Alfred; Rautenberg, Wilfried  
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 105 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE  |
|---------------|------|----------|-----------------|---|
| WO 2005042520 | A1   | 20050512 | WO 2004-EPI1550 | 20041014 <--<br>W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, |


GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LH, LV, MA, MD, MK, MN, MW, MX, MZ, NA, NI,  
NG, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SI, SV, SR, SU, SV,  
TJ, TZ, TN, TR, TE, TZ, GA, SG, US, UZ, VC, VN, YE, ZA, ZM,  
RN: BW, BY, CG, KE, LI, MZ, NA, SD, SE, SZ, TZ, UG, ZA, ZM, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

DE 10349587 A1 20050525 DE 2003-10349587 20031024 <--  
AU 2004285643 A1 20050512 AU 2004-285643 20041014 <--  
CA 2543346 A1 20050512 CA 2004-2543346 20041014 <--  
EP 1675849 A1 20060705 EP 2004-765962 20041014 <--  
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
CN 1871232 A 20061129 CN 2004-80031334 20041014 <--  
BR 2004015760 A 20061219 BR 2004-15760 20041014 <--  
JP 2007509066 T 20061102 JP 2006-509066 20061014 <--  
MX 2006004405 A 20060614 MX 2006-4405 20060420 <--  
US 2007006560 A 20061201 KR 2006-707939 20060424 <--  
US 2007006560 A1 20070322 US 2006-577033 20060424 <--  
US 7470702 B2 20081230  
IN 2006KN01239 A 20070427 IN 2006-KN1239 20060511 <--  
ZA 2006004148 A 20070926 ZA 2006-4148 20060523 <--  
US 20090082404 A1 20090326 US 2008-328320 20081204 <--  
PRIORITY APPLN. INFO.: DE 2003-10349587 A 20031024 <--  
WO 2004-EPI1550 W 20041014 <--  
US 2006-577033 A3 20060424


OTHER SOURCE(S): MARPAT 142:463726  
IT 851677-44-6P, (6-Nitro-1H-benzimidazol-2-yl)[4-(4-pyridin-4-yl oxy)phenyl]amine 851677-52-6P  
RL: PA (Pharmacological activity); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses) preparation of benzimidazolyls as Tie-2 tyrosine kinase inhibitors for the treatment of tumors

RN 851677-44-6 CAPLUS  
CN 1H-Benzimidazole-2-amine, 6-nitro-N-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 851677-52-6 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
 (3 CITINGS)  
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 6 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:76237 CAPLUS <>LOGINID::20091110>>  
 DOCUMENT NUMBER: 142:176860  
 TITLE: Preparation of thienopyrimidine derivatives as ErbB kinase inhibitors  
 INVENTOR(S): Dickerson, Scott; Howard, Emerson, Holly Kathleen;  
 Hinrichs, Kevin Wayne; Hornberger, Keith Robert;  
 Sommard, Douglas McCord; Smith, Stephan; Stevens, Kirk  
 Lawrence; Hubbard, Robert Dale; Petrow, Kimmerly  
 Glennon, Renn, Michael John; Denling, David Edward;  
 Watson, Alex Gregory  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 241 pp.  
 CODEN: PIIXKD  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE        |
|---------------|------|----------|-----------------|-------------|
| WO 2005007083 | A2   | 20050127 | WO 2004-US19410 | 20040617 << |
| WO 2005007083 | A3   | 20050421 |                 |             |

W: AE, AG, AL, AM, AT, AR, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YD, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BS, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-479324P F 20030618 <<  
 OTHER SOURCE(S): CASREACT 142:176860; MARPAT 142:176860  
 IT 833475-75-5P, N-(4-Fluorophenyl)-N'-[6-((2R)-2-pyrrolidinyl)ethyl]thieno[3,2-d]pyrimidin-4-yl]-1H-benzimidazole-2,5-diamine  
 RU 200411000000 (Pharmacological activity); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); FREP (Preparation); USES (Uses)  
 (Drug candidate; preparation of thienopyrimidines as ErbB kinase inhibitors)  
 SN 833475-75-5 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N2-(4-fluorophenyl)-N6-[6-((2R)-2-pyrrolidinyl)ethyl]thieno[3,2-d]pyrimidin-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
 (3 CITINGS)  
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 7 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:14275 CAPLUS <>LOGINID::20091110>>  
 DOCUMENT NUMBER: 142:14106  
 TITLE: Preparation of heterocyclic compounds for preventing and treating disorders associated with excessive bone loss  
 INVENTOR(S): Ono, Mitsunori; Sun, Lijun; Wada, Yumiko; Koya, Keizo;  
 Nagai, Masazumi  
 PATENT ASSIGNEE(S): Syntex Pharmaceuticals, Corp., USA  
 SOURCE: PCT Int. Appl., 151 pp.  
 CODEN: PIIXKD  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE        |
|---------------|------|----------|-----------------|-------------|
| WO 2005000404 | A2   | 20050106 | WO 2004-US17064 | 20040528 << |
| WO 2005000404 | A3   | 20050915 |                 |             |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TW, UA, UG, UZ, VA, VE, US, UT, VN, UU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZR, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG


AU 2004251641 A1 20050106 AU 2004-251641 20040528 <<  
 CA 2527079 A1 20050105 CA 2004-2527079 20040528 <<  
 EP 1626725 A2 20060222 EP 2004-776190 20040528 <<  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, RG, CZ, FE, HU, PL, SK, HR

JP 2007500241 T 20070111 JP 2006-533518 20040528 <--  
 US 20080058297 A1 20080306 US 2006-561025 20060519 <--  
 PRIORITY APPLN. INFO.: US 2003-474410P P 20030529 <--  
 US 2003-474502P P 20030529 <--  
 US 2003-474550P P 20030529 <--  
 WO 2004-US17064 W 20040528 <--

OTHER SOURCE(S): MARPAT 142:114106  
 IT 602337-78-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrimidines, triazines and purines for preventing and treating disorders associated with excessive bone loss)

RN 682337-78-6 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 7-fluoro-N-(3-methylphenyl)-4,6-di-4-morpholinyl- (CA INDEX NAME)



US CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 8 OF 36 CAPLUS COPYRIGHT 2009 ACS OR STN  
 ACCESION NUMBER: 2004-817883 CAPLUS <>LOGINID:20091110>>

DOCUMENT NUMBER: 141:332190  
 TITLE: Preparation of fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors

INVENTOR(S): Dipietro, Lucian V.; Harnange, Jean-Christophe; Askew, Benny C., Jr.; Elbaum, Daniel; Germain, Julie; Habgood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.; Potashman, Michele; Van der Ples, Simon

PATENT ASSIGNEE(S): Amgen Inc., USA  
 SOURCE: PCT Int. Appl., 289 pp.

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| PATENT NO.    | KIND  | DATE     | APPLICATION NO. | DATE         |
|---------------|---|----------|-----------------|--------------|
| WO 2004085425 | A1  | 20040107 | WO 2004-US809   | 20040322 <-- |
| W:            | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, |          |                 |              |

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TR, TZ, UA, UD, US, UZ, VG, VN, VI, DK, EH, ZW  
 RN: 1J, TM, TR, TZ, UA, UD, US, UZ, VG, VN, VI, DK, EH, ZW, AM, A2, BY, CZ, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 7531553 B2 20090512 US 2004-804915 20040319 <--

US 20040209892 A1 20041021

AU 2004223827 A1 20041007 AU 2004-223827 20040322 <--

AU 2004223827 B2 20080306

CA 2518909 A1 20041007 CA 2004-2518909 20040322 <--

EP 1638954 A1 20060329 EP 2004-758050 20040322 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

JP 2006520805 T 20060914 JP 2006-507472 20040319 <--

MX 2005510086 A 20060210 MX 2005-510086 20040322 <--

PRIORITY APPLN. INFO.: US 2004-456691P P 20030321 <--

US 2004-804915 A 20040319 <--

WO 2004-US8093 A 20040322 <--

OTHER SOURCE(S): MARPAT 141:332190

IT 1055984-37-6P 1055984-58-1P 1055984-62-7P


1055985-13-1P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)


RN 1055984-37-6 CAPLUS

CN 3-Pyridinocarboxamide, 4-[(2-((3,4-dichlorophenyl)amino)-3-benzimidazol-6-yl)amino]N-methyl- (CA INDEX NAME)




RN 1055984-58-1 CAPLUS


CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)-N6-(6,7-dimethoxy-4-quinolinyl)- (CA INDEX NAME)



RN 1055984-62-7 CAPLUS  
 CN 1H-Benzimidazole-2,6-diamine, N2-(4-cyclohexylphenyl)-N6-(2-(methylamino)-4-pyrimidinyl)- (CA INDEX NAME)



RN 1055985-13-1 CAPLUS  
 CN 1H-Benzimidazole-2,6-diamine, N2-(3-fluorophenyl)-N6-4-quinolinyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
 REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 9 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
 ACCESSION NUMBER: 2004:513393 CAPLUS <<LOGINID::20091110>>  
 DOCUMENT NUMBER: 141:71544  
 TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors  
 INVENTOR(S): Anuri, Payman; Funti, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sheradha; Sung, Leonard  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| PATENT NO.     | KIND | DATE     | APPLICATION NO. | DATE         |
|----------------|------|----------|-----------------|--------------|
| US 20040122237 | A1   | 20040624 | US 2003-675927  | 20030929 <-- |
| US 20040087626 | A1   | 20040506 | US 2003-405945  | 20030331 <-- |
| US 7071216     | B2   | 20060704 |                 |              |

AU 2004277405 A1 20050414 AU 2004-277405 20040929 <--  
 CA 2539748 A1 20050414 CA 2004-2539748 20040929 <--  
 WO 2005025450 A1 20050414 WO 2004-0532161 20040929 <--  
 W: AF, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, RJ, CF, CG, CI, CM, GA, GN, CQ, GW, ML, MR, NE,  
 SN, TD, TG

EP 1575584 A1 20060705 EP 2004-789345 20040929 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 LI, SI, FI, RO, CY, MK, PL, CZ, EE, HU, PE, SK

BR 2004014908 A 20051107 BR 2004-14908 20040929 <--

CN 1913884 A 20070214 CN 2004-80032677 20040929 <--

JP 2007507428 T 20070329 JP 2004-520331 20040929 <--

US 2006239303 A1 20071227 US 2005-282939 20051118 <--

MX 2006003435 A 20060620 MX 2006-3435 20060327 <--

JP 2006193533 A 20060527 JP 2006-96143 20060330 <--

KR 2006089232 A 20060808 KR 2006-706470 20060403 <--

IN 2006KN00838 A 20070413 IN 2006-KN838 20060405 <--

ZA 2006003418 A 20070725 ZA 2006-3418 20060428 <--

PRIORITY APPLN. INFO.:

US 2002-369066P P 20020329 <--

US 2003-405945 A2 20030331 <--

JP 2003-579810 A3 20030331 <--

US 2003-675927 A 20030929 <--

WO 2004-0532161 W 20040929 <--


OTHER SOURCE(S): MARPAT 141:71544

IT 611220-17-8P RLU: RC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses) (Rat kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

RN 611220-17-8 CAPLUS

CN 2-Pyridinecarboxamide, 4-[{2-[4-(4-bromophenyl)amino]-1H-benzimidazol-6-yl}amino]-N-methyl- (CA INDEX NAME)




IT 611225-93-5P RLU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Intermediate; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)

RN 611225-93-5 CAPLUS

CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

L5 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:355045 CAPLUS <>LOGINID::20091110>>  
 DOCUMENT NUMBER: 140:357119  
 TITLE: Preparation of amino morpholinopurine derivatives for  
 treating interleukin-12 overproduction-related  
 disorders  
 INVENTOR(S): Sun, Lijun; Ono, Mitsuori; Wada, Yumiko; Ying,  
 Weiwen; Prawiorka, Teresa; Kostik, Elena  
 PATENT ASSIGNEE(S): Syntex Pharmaceuticals Corp., USA  
 SOURCE: PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE           |
|--|------|----------|-----------------|----------------|
| WO 2004035740  | A2   | 20040429 | WO 2003-US32546 | 20031014 <<    |
| WO 2004035740  | A3   | 20041216 |                 |                |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,<br>CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,<br>GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS,<br>LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,<br>PL, PT, RU, SD, SE, SI, SL, TJ, TM, TN, TR, TT, TZ,<br>UA, US, UZ, VU, ZA, ZM, ZW |      |          |                 |                |
| RN: GH, GM, KE, LS, MM, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,<br>KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,<br>FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,<br>PF, RJ, CF, CG, CI, CM, GA, GN, CO, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |                |
| CA 2502356   | A1   | 20040429 | CA 2003-2502356 | 20031014 <<    |
| AU 2003284142  | A1   | 20040504 | AU 2003-284142  | 20031014 <<    |
| US 20040198725   | A1   | 20041007 | US 2003-686505  | 20031014 <<    |
| US 7122665   | B2   | 20061017 |                 |                |
| EP 1556140   | A2   | 20050727 | EP 2003-776373  | 20031014 <<    |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |                |
| JP 2006507273  | T    | 20062302 | JP 2004-545265  | 20031014 <<    |
| US 20070027151   | A1   | 20070201 | US 2006-542963  | 20061003 <<    |
| US 7410940   | B2   | 20080512 |                 |                |
| PRIORITY APPLN. INFO.:   |      |          | US 2002-41994P  | P 20021015 <<  |
| IT 602337-78-6P  |      |          | US 2003-686505  | A1 20031014 << |
| RL: PAC (Pharmacological activity); SBN (Synthetic preparation); THU<br>(Therapeutic use); BIOL (Biological study); PREP (Preparation); NSES   |      |          | WO 2003-US32546 | W 20031014 <<  |

OTHER SOURCE(S): MARPAT 140:357119

IT 602337-78-6P


RL: PAC (Pharmacological activity); SBN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); NSES

(Uses)

(preparation of amino morpholinopurine derivs. for treating interleukin-12  
 overprod.-related disorders)

RN 602337-78-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 7-fluoro-N-(3-methylphenyl)-4,6-di-4-morpholinyl-  
 (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:6498 CAPLUS <>LOGINID::20091110>>  
 DOCUMENT NUMBER: 141:136262  
 TITLE: Molecular Modeling and Design of Radiolabelled  
 Complexes for Melanoma Diagnosis  
 AUTHOR(S): Tuttle, C. T.; Tell, Seabrook, Shane A.; Wise, Lauren  
 E.; Katsifis, Andrew; Knott, Robert B.; Yates, Brian  
 F.  
 CORPORATE SOURCE: School of Chemistry, University of Tasmania, Hobart,  
 TAS 7001, Australia  
 SOURCE: Australian Journal of Chemistry (2004),  
 57(1), 77-96  
 CODEN: AJCHAS; ISSN: 0004-9425  
 PUBLISHER: CSIRO Publishing  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 727408-66-4  
 RL: BSB (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (integrin receptor-binding)  
 RN 727408-66-4 CAPLUS  
 CN L-Alanine, 3-[(7-nitro-2-(phenylamino)-1H-benzimidazol-5-  
 yl)carbonyl]amino-N-(phenylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
 REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 12 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:736477 CAPLUS <>LOGINID:20091110>>  
 DOCUMENT NUMBER: 139:307759  
 TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors  
 INVENTOR(S): Renhong, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levino, Barry Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fanti, Wendy  
 PATENT ASSIGNEE(S): Chiron Corporation, USA  
 SOURCE: PCT Int. Appl., 259 pp.


DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE         |
|---|------|----------|-----------------|--------------|
| WO 2003082272   | A1   | 20031009 | WO 2003-US10117 | 20030331 <-- |
| W: AE, AG, AL, AM, AT, AU, AR, BA, BE, BY, BZ, CA, CB, CN, CO, CR, DE, DK, DM, DZ, EC, ES, FI, GE, GD, GH, GN, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |              |
| RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CR, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |              |
| CA 2490638  | A1   | 20031009 | CA 2003-2480638 | 20030331 <-- |
| AU 2003226211   | A1   | 20031013 | AU 2003-226211  | 20030331 <-- |
| AU 2003226211   | B2   | 20080529 |                 |              |
| EP 1499311  | A1   | 20050126 | EP 2003-745683  | 20030331 <-- |
| EP 1499311  | B1   | 20041104 |                 |              |
| R: AT, BE, CH, DE, DK, EL, ES, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, ST, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HD, SK   |      |          |                 |              |
| BR 2003008854   | A    | 20050222 | BR 2003-8854    | 20030331 <-- |
| BR 2003008854   | A    | 20050817 | CN 2003-612193  | 20030331 <-- |
| CN 100515418  | C    | 20090722 |                 |              |
| JP 2005523089   | T    | 20050429 | JP 2003-574810  | 20030331 <-- |
| NZ 535985   | A    | 20070427 | NZ 2003-535985  | 20030331 <-- |
| AU 1913   | A    | 20081031 | AP 2004-3161    | 20030331 <-- |
| IN 2004KN01433  | A    | 20051230 | IN 2004-KN1433  | 20040927 <-- |
| MX 2004009541   | A    | 20050125 | MX 2004-9541    | 20040929 <-- |

NO 2004004617 A 20041228 NO 2004-4617 20041026 <--  
 2A 2004008386 A 20060531 2A 2004-8386 20060308 <--  
 JP 2006193533 A 20060727 JP 2006-96143 20060330 <--  
 P 20020329 <--  
 US 2002-369066P P 20020329 <--  
 JP 2001-579810 A3 20010331 <--  
 WO 2001-US10117 W 20010331 <--


OTHER SOURCE(S): MARPAT 139:307759  
 IT 611220-17-8P  
 RL: PAC (Pharmacological activity); SPA (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted benzazoles as Raf kinase inhibitors)

RN 611220-17-8 CAPLUS  
 CN 2-Pyridinecarboxamide, 4-[(2-[(4-bromophenyl)amino]-1H-benzimidazol-6-yl)amino]-N-methyl- (CA INDEX NAME)



IT 611225-93-5P  
 RL: RCT (Reactant); SPA (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of substituted benzazoles as Raf kinase inhibitors)


RN 611225-93-5 CAPLUS  
 CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 13 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:719473 CAPLUS <>LOGINID:20091110>>  
 DOCUMENT NUMBER: 139:246042  
 TITLE: Preparation of benzimidazolylamino arylamino pyrimidine TIE-2 and/or VEGFR inhibitors and their use as angiogenesis inhibitors  
 INVENTOR(S): Chamberlain, Stanley Dawes; Cheung, Mui; Emerson, Holly Kathleen; Johnson, Neil W.; Naylor, Kristen Elizabeth; Sammond, Douglas McCord; Semones, Marcus Smith; Smithkline Beecham Corporation, USA  
 PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 253 pp.






RN 596132-73-9 CAPLUS  
CN Carbanic acid, (4-methoxyphenyl)[1-methyl-5-[methyl(2-[(3-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl)amino]-1H-benzimidazol-2-yl]-1,1-dimethyl ester (9CI) (CA INDEX NAME)



596132-76-2 CAPLUS  
Carbamic acid, (4-methoxyphenyl)[1-methyl-5-[methyl[2-[(4-[1-methylsulfonyl]phenyl)amino]-4-pyrimidinyl]amino]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 5561-31-79-2P, *N*<sup>1</sup>-Methyl-1-methyl-N<sup>2</sup>-(4-[4-(*Methyl*amino)phenyl]amino)pyrimidin-4-yl)-*N*-phenyl-1H-benzimidazole-2,5-diamine 5561-31-80-5P, 5561-32-36-4P, 3-[(4-[*Methyl*amino]2-phenylamino-1H-benzimidazol-5-yl)amino]pyrimidin-2-yl)amino)benzenesulfonamide 5561-32-37-5P, 3-[(4-[*Methyl*amino]2-phenylamino-1H-benzimidazol-5-yl)amino]pyrimidin-2-yl)amino)benzenesulfonamide trifluoroacetate 5561-32-39-7P, *N*<sup>1</sup>-(2-[(3-Methanesulfonyl)-4-methylphenyl]amino)pyrimidin-4-yl)-1-methyl-*N*<sup>2</sup>-(4-[*Methyl*amino]1-methyl-2-phenylamino-1H-benzimidazole-2,5-diamine 5561-32-40-0P 5561-32-41-1, 1-[(4-[*Methyl*amino]2-phenylamino-1H-

benzimidazol-5-yl)amino]pyrimidin-2-yl]amino]phenyl)methanesulfonamide  
 596132-42-2P, [4-[(4-Methyl-1-methyl-2-phenylamino)-1H-  
 benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl)methanesulfonamide  
 trifluoroacetate 596132-43-3P, Methanesulfonic acid  
 4-[(4-[Imethyl-1-(methyl-2-phenylamino)-1H-benzimidazol-5-yl]amino)pyrimidin-  
 2-yl]amino]phenyl ester 596132-44-4P, Methanesulfonic acid  
 4-[(4-[methyl-1-(methyl-2-phenylamino)-1H-benzimidazol-5-yl]amino)pyrimidin-  
 2-yl]amino]phenyl ester trifluoroacetate 596132-45-5P,  
 3-[(4-[(2-[(4-Fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-yl]amino]benzenesulfonamide  
 596132-46-6P, 3-[(4-[(2-[(4-Fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-yl]amino]benzenesulfonamide  
 trifluoroacetate 596132-47-7P,  
 4-[(4-[(2-[(4-Fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-yl]amino]benzenesulfonamide  
 596132-48-8P, 5-[(4-[(2-[(4-Fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-yl]amino]-2-  
 methylbenzenesulfonamide trifluoroacetate 596132-49-9P,  
 N-(4-Fluorophenyl)-N'-[2-[(4-  
 [(methanesulfonyl)ethyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-  
 1H-benzimidazole-2,5-diamine 596132-50-2P  
 596132-51-3P, 1-[(4-[(2-[(4-Fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-  
 yl]amino]phenyl)methanesulfonamide 596132-52-4P,  
 4-[(4-[(2-[(4-Fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-  
 yl)methyl]amino)pyrimidin-2-yl]amino]phenyl)methanesulfonamide  
 trifluoroacetate 596132-53-5P, Methanesulfonic acid  
 4-[(4-[(2-[(4-Fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-yl]amino]phenyl ester  
 trifluoroacetate 596132-54-6P  
 Methanesulfonic acid 4-[(4-[(2-[(4-Fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-yl]amino]phenyl ester  
 trifluoroacetate 596132-55-7P, Methanesulfonic acid  
 3-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-  
 yl]amino]phenyl ester 596132-56-8P  
 Methanesulfonic acid 3-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-yl]amino]phenyl ester  
 trifluoroacetate 596132-58-0P  
 N'-[2-[(4-[(Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-1-methyl-  
 1H-methyl-N'-p-tolyl-1H-benzimidazole-2,5-diamine 596132-59-1P  
 596132-60-4P, 1-[(4-[(2-[(4-tert-Butylphenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-  
 yl]amino]phenyl)methanesulfonamide 596132-61-5P,  
 4-[(4-[(2-[(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-  
 yl)methyl]amino)pyrimidin-2-yl]amino]phenyl)methanesulfonamide  
 trifluoroacetate 596132-62-6P  
 4-[(4-[(2-[(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-  
 yl)methyl]amino)pyrimidin-2-yl]amino]benzenesulfonamide  
 596132-63-7P, 3-[(4-[(2-[(4-tert-Butylphenyl)amino]-1-methyl-1H-  
 benzimidazol-5-yl)methyl]amino)pyrimidin-2-yl]amino]benzenesulfonamide  
 trifluoroacetate 596132-64-8P,  
 5-[(4-[(2-[(4-tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-  
 yl)methyl]amino)pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide  
 hydrochloride 596132-65-4P,  
 N-4-tert-Butylphenyl)-N'-[2-[(4-  
 [(methanesulfonyl)ethyl]phenyl)amino]pyrimidin-4-yl]-1-methyl-N'-methyl-  
 1H-benzimidazole-2,5-diamine 596132-66-0P  
 596132-67-3P, 596132-74-0P,  
 N'-[2-[(4-[(Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N-(4-  
 methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine  
 596132-75-1P, 596132-77-3P  
 N'-[2-[(4-[(Methanesulfonyl)ethyl]phenyl)amino]pyrimidin-4-yl]-N-(4-  
 methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine


methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine  
 596132-78-4P 596132-79-5P,  
 N'-[2-[(3-[1-(Methanesulfonyl)ethyl]phenyl)amino]pyrimidin-4-yl]-N-(4-methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine  
 596132-80-8P 596132-85-0P,  
 1-Methyl-N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-trifluoromethylphenyl)-1H-benzimidazole-2,5-diamine  
 596132-96-1P, 1-Methyl-N'-[2-[(4-  
 [Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N'-methyl-N-(3-chlorophenyl)-1H-benzimidazole-2,5-diamine 596133-07-2P,  
 1-Methyl-N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-chlorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-08-3P, 1-Methyl-N'-[2-[(4-  
 [Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N'-methyl-N-(2,4-dichlorophenyl)-1H-benzimidazole-2,5-diamine 596133-09-4P,  
 1-Methyl-N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2,5-dichlorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-10-7P, 1-Methyl-N'-[2-[(4-  
 [Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-4-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine  
 596133-11-8P, 1-Methyl-N'-[2-[(4-  
 [Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-4-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine  
 596133-12-9P, 1-Methyl-N'-[2-[(4-  
 [Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N'-methyl-N-(4-morpholinophenyl)-1H-benzimidazole-2,5-diamine 596133-13-0P,  
 1-Methyl-N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(3-(fluorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-14-1P, 1-Methyl-N'-[2-[(4-  
 [Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N'-methyl-N-(2,4-difluorophenyl)-1H-benzimidazole-2,5-diamine 596133-15-2P,  
 1-Methyl-N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-4-(fluorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-16-3P, 1-Methyl-N'-[2-[(4-  
 [Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N'-methyl-N-(4-chloro-2-(fluorophenyl)-1H-benzimidazole-2,5-diamine 596133-17-4P,  
 1-Methyl-N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-5-(fluorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-18-5P, 1-Methyl-N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-4-(methylphenyl)-1H-benzimidazole-2,5-diamine  
 596133-19-6P, 1-Methyl-N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-(methylphenyl)-1H-benzimidazole-2,5-diamine  
 596133-21-0P, 1-Methyl-N'-[2-[(4-  
 [Methanesulfonyl)methyl]phenyl)amino]pyrimidin-4-yl]-N'-methyl-N-(2-fluoro-5-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine  
 596133-26-5P, 4-[4-(Methyl-1-methyl-2-[(4-trifluoromethylphenyl)amino]benzenesulfonamide-1H-benzimidazol-5-yl]amino]pyrimidin-2-ylamino]benzenesulfonamide 596133-35-6P,  
 N'-[2-[(4-(Methanesulfonyl)methyl)phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-N-(3-trifluoromethylphenyl)-1H-benzimidazole-2,5-diamine  
 596135-00-1P, Phenyll-1-Methyl-5-[methyl]2-[(3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]-1H-benzimidazol-2-yl]carbamic acid tert-butyl ester 596135-01-2P,  
 (Phenyl)[1-Methyl-5-(methyl)-2-[(4-methyl-1-sulfamoylphenyl)amino]pyrimidin-4-yl]-1-1H-benzimidazol-2-yl]carbamic acid tert-butyl ester  
 596135-02-3P, 5-[methyl]-2-[(4-Tert-Butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); RIOL (Biological study); PREP (Preparation); USES

(Uses)  
 (drug candidate; preparation of benzimidazolylamino arylamino pyrimidine  
 716-2-0 and/or VEGFR inhibitors and their use as angiogenesis inhibitors)  
 RN 596131-79-2 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl-N2-phenyl- (CA INDEX NAME)



RN 596131-80-5 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl-N2-phenyl-, 2,2-trifluoracetate (1:1) (CA INDEX NAME)


CM 1  
 CRN 596131-79-2  
 CMF C27 H27 N7 O2 S




CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 596132-36-4 CAPLUS  
 CN Benzenesulfonamide, 3-[(4-(methyl-1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl)amino)-2-pyrimidinyl]amino- (CA INDEX NAME)




RN 596132-37-5 CAPLUS  
 CN Benzenesulfonamide, 3-[(4-[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino)-2-pyrimidinyl]amino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 596132-36-4  
 CMF C25 H24 N8 O2 S



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 596132-39-7 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-(2-((4-methyl-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-N2-phenyl- (CA INDEX NAME)



RN 596132-40-0 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-(2-((4-methyl-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-N2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 596132-39-7  
 CMF C27 H27 N7 O2 S



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 596132-41-1 CAPLUS  
 CN Benzenemethanesulfonamide, 4-[(4-(methyl-2-(phenylamino)-1H-benzimidazol-5-yl)amino)-2-pyrimidinyl]amino- (CA INDEX NAME)



RN 596132-42-2 CAPLUS  
 CN Benzenemethanesulfonamide, 4-[(4-(methyl-2-(phenylamino)-1H-benzimidazol-5-yl)amino)-2-pyrimidinyl]amino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-41-1  
CMF C26 H26 N8 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-43-3 CAPLUS  
CN Phenol, 4-[(4-methyl-1-methylethyl-2-(phenylamino)-1H-benzimidazol-5-yl)amino]-2-pyrimidinylamino-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-44-4 CAPLUS  
CN Phenol, 4-[(4-methyl-1-methylethyl-2-(phenylamino)-1H-benzimidazol-5-yl)amino]-2-pyrimidinylamino-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-43-3  
CMF C26 H25 N7 O3 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-45-5 CAPLUS  
CN Benzenesulfonamide, 3-[(4-[(2-[(4-fluorophenyl)amino]-1-methylethyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]- (CA INDEX NAME)



RN 596132-46-6 CAPLUS  
CN Benzenesulfonamide, 3-[(4-[(2-[(4-fluorophenyl)amino]-1-methylethyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-45-5  
CMF C25 H23 F N8 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-47-7 CAPLUS  
CN Benzenesulfonamide, 5-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-2-methyl- (CA INDEX NAME)



RN 596132-48-8 CAPLUS  
CN Benzenesulfonamide, 5-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-2-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-47-7  
CMF C26 H25 F NB O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 596132-49-9 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-fluorophenyl)-N5,1-dimethyl-N5-(2-[(4-methylsulfonyl)methyl]phenyl)amino)-4-pyrimidinyl- (CA INDEX NAME)




RN 596132-50-2 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(4-fluorophenyl)-N5,1-dimethyl-N5-(2-[(4-methylsulfonyl)methyl]phenyl)amino)-4-pyrimidinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-49-9  
CMF C27 H26 F N7 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-51-3 CAPLUS  
CN Benzenemethanesulfonamide, 4-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]- (CA INDEX NAME)



RN 596132-52-4 CAPLUS  
CN Benzenemethanesulfonamide, 4-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-51-3  
CMF C26 H25 F N8 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-53-5 CAPLUS  
CN Phenol, 4-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-54-6 CAPLUS  
CN Phenol, 4-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-53-5  
CMF C26 H24 F N7 O3 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-55-7 CAPLUS  
CN Phenol, 3-[(4-[(2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-56-8 CAPLUS  
 CN Phenol, 3-[(4-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methyl]-2-pyrimidinylamino]-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-55-7  
 CMF C26 H24 F N7 O3 S




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 596132-58-0 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N2-(4-methylphenyl)-N5-(2-[(4-(methylsulfonyl)methyl)phenyl]amino)-4-pyrimidinyl] (CA INDEX NAME)



RN 596132-59-1 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N2-(4-methylphenyl)-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-58-0  
 CMF C28 H29 N7 O2 S




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 596132-60-4 CAPLUS  
 CN Benzenemethanesulfonamide, 4-[(2-[(4-(1,1-dimethylethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methyl]amino]- (CA INDEX NAME)



RN 596132-61-5 CAPLUS  
 CN Benzenemethanesulfonamide, 4-[(2-[(4-(1,1-dimethylethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methyl]amino]-2-pyrimidinylamino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1  
CRN 596132-60-4  
CMF C30 H34 N8 O2 S



CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-62-6 CAPLUS  
CN Benzenesulfonamide, 3-[(4-[(2-[(4-(1,1-dimethylethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]- (CA INDEX NAME)



RN 596132-63-7 CAPLUS  
CN Benzenesulfonamide, 3-[(4-[(2-[(4-(1,1-dimethylethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1  
CRN 596132-62-6  
CMF C29 H32 N8 O2 S



CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-64-8 CAPLUS  
CN Benzenesulfonamide, 5-[(4-[(2-[(4-(1,1-dimethylethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl)methylamino]-2-pyrimidinyl)amino]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 596132-65-9 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-(1,1-dimethylethyl)phenyl)-N5,1-dimethyl-N5-[(2-[(4-(methylsulfonyl)methyl)phenyl]amino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 596132-66-0 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N2-[4-(1,1-dimethylethyl)phenyl]-N5,1-dimethyl-N5-[2-[(4-[methylsulfonyl]methyl)phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 596132-65-9  
 CMF C31 H35 N7 O2 S



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 596132-69-3 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[(4-[methylsulfonyl]methyl)phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 596132-68-2  
 CMF C28 H29 N7 O3 S



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 596132-74-0 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[(3-[methylsulfonyl]methyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596132-75-1 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[(3-[methylsulfonyl]methyl)phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
 CRN 596132-74-0  
 CMF C28 H29 N7 O3 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-77-3 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-(2-[(4-(1-(methylsulfonyl)ethyl)phenyl)amino]-4-pyrimidinyl)- (CA INDEX NAME)



RN 596132-78-4 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-(2-[(4-(1-(methylsulfonyl)ethyl)phenyl)amino]-4-pyrimidinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-77-3  
CMF C29 H31 N7 O3 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-79-5 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[(3-(1-(methylsulfonyl)ethyl)phenyl)amino]-4-pyrimidinyl)- (CA INDEX NAME)



RN 596132-80-8 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[(3-(1-(methylsulfonyl)ethyl)phenyl)amino]-4-pyrimidinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 596132-79-5  
CMF C29 H31 N7 O3 S




CM 2  
CRN 76-05-1  
CME C2 H F3 O2




RN 596133-05-0 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methylphenylamino)-4-pyrimidinyl]-N2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 596133-06-1 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(3-chlorophenyl)-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl- (CA INDEX NAME)




RN 596133-07-2 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-chlorophenyl)-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl- (CA INDEX NAME)




RN 596133-08-3 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2,4-dichlorophenyl)-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl- (CA INDEX NAME)




RN 596133-09-4 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2,5-dichlorophenyl)-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl- (CA INDEX NAME)




RN 596133-10-7 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-[2-chloro-4-(trifluoromethyl)phenyl]-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl- (CA INDEX NAME)




RN 596133-11-8 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-5-(trifluoromethyl)phenyl)-N5,1-dimethyl-N5-[2-[(4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-12-9 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[(4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 596133-13-0 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(3-fluorophenyl)-N5,1-dimethyl-N5-[2-[(4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-14-1 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2,4-difluorophenyl)-N5,1-dimethyl-N5-[2-[(4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-15-2 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-4-fluorophenyl)-N5,1-dimethyl-N5-[2-[(4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-16-3 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-chloro-2-fluorophenyl)-N5,1-dimethyl-N5-[2-[(4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-17-4 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-5-fluorophenyl)-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl] (CA INDEX NAME)




RN 596133-18-5 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-fluoro-4-methylphenyl)-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl] (CA INDEX NAME)




RN 596133-20-9 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-fluorophenyl)-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl] (CA INDEX NAME)




RN 596133-21-0 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-fluoro-5-(trifluoromethyl)phenyl)-N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl] (CA INDEX NAME)




RN 596133-26-5 CAPLUS  
CN Benzene sulphonamide, 4-[(4-[methyl(1-methyl-2-[(4-(trifluoromethyl)phenyl)amino]-1H-benzimidazol-5-yl)amino)-2-pyrimidinyl]amino] (CA INDEX NAME)




RN 596133-35-6 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[(4-(methylsulfonyl)methyl)phenyl]amino]-4-pyrimidinyl]-N2-[3-(trifluoromethyl)phenyl] (CA INDEX NAME)




RN 596135-00-1 CAPLUS  
 CN Carbamic acid, [5-[(2-[(3-(aminosulfonyl)phenyl]amino)-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)



RN 596135-01-2 CAPLUS  
 CN Carbamic acid, [5-[(2-[(3-(aminosulfonyl)-4-methylphenyl]amino)-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)




RN 596135-02-3 CAPLUS  
 CN Benzene-1-sulfonamide, 5-[(4-[(2-[(4-(1,1-dimethylethyl)phenyl]amino)-1-methyl-1H-benzimidazol-2-yl]methylamino)-2-pyrimidinyl]amino)-2-methyl- (CA INDEX NAME)




IT 596130-89-1P, tert-Butyl [5-[(2-chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl]phenyl] carbamate 596130-90-4P, 1-Methyl-5-nitro-N-phenyl-1H-benzimidazol-2-yl)phenylcarbamate 596130-91-5P, tert-Butyl (1-methyl-5-nitro-1H-benzimidazol-2-yl)phenylcarbamate 596130-92-6P, tert-Butyl (5-amino-1-methyl-1H-benzimidazol-2-yl)phenylcarbamate 596130-93-7P, tert-Butyl (5-[(2-chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl)phenylcarbamate 596131-27-0P, [5-[(2-Chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl] (4-fluorophenyl)carbamic acid tert-butyl ester 596131-28-1P, (4-Fluorophenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)amine 596131-29-2P, (5-Amino-1-methyl-1H-benzimidazol-2-yl) (4-fluorophenyl)carbamic acid tert-butyl ester 596131-30-5P, [5-[(2-Chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl] (4-fluorophenyl)carbamic acid tert-butyl ester 596131-31-6P, [5-[(2-Chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl]-p-tolylcarbamic acid tert-butyl ester 596131-32-7P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl)-p-tolylamine 596131-33-8P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl)-p-tolylcarbamic acid tert-butyl ester 596131-34-9P, (5-Amino-1-methyl-1H-benzimidazol-2-yl)-p-tolylcarbamic acid tert-butyl ester 596131-35-0P, (5-[(2-Chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl) (4-tert-butylphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)amine 596131-38-3P, (4-tert-Butylphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)carbamic acid tert-butyl ester 596131-39-4P, (5-Amino-1-methyl-1H-benzimidazol-2-yl) (4-tert-butylphenyl)carbamic acid tert-butyl ester 596131-40-7P, (4-tert-Butylphenyl) [5-[(2-chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl]carbamic acid tert-butyl ester 596131-41-8P, N-[(2-Chloropyrimidin-4-yl)-N-(4-methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 596131-42-9P, (4-Methoxyphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)amine 596131-43-0P, (4-Methoxyphenyl) (1-methyl-5-nitro-1H-benzimidazol-2-yl)carbamic acid tert-butyl ester 596131-44-1P, (5-Amino-1-methyl-1H-benzimidazol-2-yl) (4-methoxyphenyl)carbamic acid tert-butyl ester 596131-45-2P, (5-[(2-Chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl) (4-methoxyphenyl)carbamic acid tert-butyl ester 596131-46-3P, [5-[(2-Chloropyrimidin-4-yl) (methyl) amino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)carbamic acid tert-butyl ester 596131-74-7P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl) (4-fluorophenyl)carbamic acid tert-butyl ester 596133-27-6P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl) (3-trifluoromethylphenyl)amine


596133-29-8P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl) (3-trifluoromethylphenyl) carbamic acid 1,1-dimethylethyl ester  
 596133-31-2P, (5-Amino-1-methyl-1H-benzimidazol-2-yl) (3-trifluoromethylphenyl) carbamic acid 1,1-dimethylethyl ester  
 596133-33-4P, [5-(2-Chloropyrimidin-4-yl) (methyl)amino]-1-methyl-1H-benzimidazol-2-yl] (3-trifluoromethylphenyl) carbamic acid 1,1-dimethylethyl ester  
 RL: (Reaction or reagent); SPM (Synthetic preparation); PREP (Preparation); RACT (Reaction or reagents)  
 (preparation of benzimidazolylamino arylamino pyrimidine TIE-2 and/or VEGFR inhibitors and their use as angiogenesis inhibitors)  
 RN 596130-89-1 CAPLUS  
 CN Carbamic acid, [5-(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-90-4 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 1-methyl-5-nitro-N-phenyl-, (CA INDEX NAME)




RN 596130-91-5 CAPLUS  
 CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-92-6 CAPLUS  
 CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-93-7 CAPLUS  
 CN Carbamic acid, (5-(2-chloro-4-pyrimidinyl)amino)-1-methyl-1H-benzimidazol-2-yl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-27-0 CAPLUS  
 CN Carbamic acid, (5-(2-chloro-4-pyrimidinyl)methylamino)-1-methyl-1H-benzimidazol-2-yl) (4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-28-1 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-nitro- (CA INDEX NAME)




RN 596131-29-2 CAPLUS  
 CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl) (4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-30-5 CAPLUS  
CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596131-31-6 CAPLUS  
CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl](4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-32-7 CAPLUS  
CN 1H-Benzimidazol-2-amine, 1-methyl-N-(4-methylphenyl)-5-nitro- (CA INDEX NAME)




RN 596131-33-8 CAPLUS


CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl)(4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-34-9 CAPLUS  
CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)(4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-35-0 CAPLUS  
CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-36-1 CAPLUS  
CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl](4-(1,1-dimethylethyl)phenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-37-2 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-[4-(1,1-dimethylethyl)phenyl]-1-methyl-5-nitro- (CA INDEX NAME)




RN 596131-38-3 CAPLUS  
CN Carbamic acid, [4-(1,1-dimethylethyl)phenyl](1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-39-4 CAPLUS  
CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-40-7 CAPLUS  
CN Carbamic acid, (5-((2-chloro-4-pyrimidinyl)amino)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-41-8 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5-(2-chloro-4-pyrimidinyl)-N2-(4-methoxyphenyl)-N5,1-dimethyl- (CA INDEX NAME)




RN 596131-42-9 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-1-methyl-5-nitro- (CA INDEX NAME)




RN 596131-43-0 CAPLUS  
CN Carbamic acid, (4-methoxyphenyl)(1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-44-1 CAPLUS  
CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)(4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-45-2 CAPLUS  
CN Carbamic acid, [5-((2-chloro-4-pyrimidinyl)amino)-1-methyl-1H-benzimidazol-2-yl)(4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-46-3 CAPLUS  
CN Carbamic acid, [5-((2-chloro-4-pyrimidinyl)methylamino)-1-methyl-1H-benzimidazol-2-yl)(4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-74-7 CAPLUS  
CN Carbamic acid, (4-fluorophenyl)(1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596133-27-6 CAPLUS  
CN 1H-Benzimidazol-2-amine, 1-methyl-5-nitro-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 596133-29-8 CAPLUS  
CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl)[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596133-31-2 CAPLUS  
CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596133-33-4 CAPLUS  
CN Carbamic acid, [5-((2-chloro-4-pyrimidinyl)methylamino)-1-methyl-1H-benzimidazol-2-yl][3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 14 OF 36 CAPLUS COPYRIGHT 2009 ACS on STW  
 ACCESSION NUMBER: 2002142711 CAPLUS <<LOGINID::2C091110>>  
 DOCUMENT NUMBER: 136-200200  
 TITLE: Preparation of imidazoquinazolinones as inhibitors of tyrosine kinases  
 INVENTOR(S): Snow, Roger John; Gao, Donghong A.; Goldberg, Daniel R.; Hammach, Abdellah; Kuzmich, Daniel; Morwick, Tina Marie; Moss, Neil; Prokopowicz, Anthony S., III; Selliah, Robert D.; Takemoto, Hidenori  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 147 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE            |
|---|------|----------|-----------------|-----------------|
| WO 2002014319   | A2   | 20020221 | WO 2001-US24390 | 20010802 <--    |
| WO 2002014319   | A3   | 20020801 |                 |                 |
| W: CA, JP, MX   |      |          |                 |                 |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR    |      |          |                 |                 |
| CA 2417635  | A1   | 20020221 | CA 2001-2417635 | 20010802 <--    |
| CA 2417635  | C    | 20080205 |                 |                 |
| US 20020119975  | A1   | 20020829 | US 2001-921510  | 20010802 <--    |
| US 6489328  | B2   | 20021203 |                 |                 |
| EP 1309596  | A2   | 20030514 | EP 2001-957425  | 20010802 <--    |
| EP 1309596  | B1   | 20080206 |                 |                 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, IE, FI, CY, TS |      |          |                 |                 |
| JP 20034506356  | T    | 20040204 | JP 2002-519459  | 20010802 <--    |
| AT 385491   | T    | 20080215 | AT 2001-957425  | 20010802 <--    |
| ES 2299501  | T3   | 20080601 | ES 2001-957425  | 20010802 <--    |
| US 20030207902  | A1   | 20031105 | US 2002-271222  | 20021015 <--    |
| US 6844435  | B2   | 20050118 |                 |                 |
| MX 2003C01306   | A    | 20031015 | MX 2003-1306    | 20030211 <--    |
| PRIORITY APPLN. INFO.:  |      |          | US 2000-225724P | P 20000911 <--  |
|   |      |          | US 2001-921510  | A3 20010802 <-- |
|   |      |          | WO 2001-US24390 | W 20010802 <--  |

OTHER SOURCE(S): MARPAT 136:200200

IT 400784-57-8P 400784-58-9P 400784-59-0P

400784-60-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation of imidazoquinazolinones as inhibitors of tyrosine kinases)


RN 400784-57-8 CAPLUS

1H-Benzimidazole-7-carbonitrile, 6-amino-2-[(2,6-dichlorophenyl)amino]-1-


methyl- (CA INDEX NAME)




RN 400784-58-9 CAPLUS  
 CN Acetamide, N-[7-cyano-2-[(2,6-dichlorophenyl)amino]-1-methyl-1H-benzimidazol-6-yl]- (CA INDEX NAME)



RN 400784-59-0 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 6-amino-2-[(2,6-dichlorophenyl)amino]-1-methyl- (CA INDEX NAME)




RN 400784-60-3 CAPLUS  
 CN 1H-Benzimidazole-7-carboxamide, 2-[(2,6-dichlorophenyl)amino]-1-methyl-6-[(2-propen-1-ylamino)thiomethyl]amino- (CA INDEX NAME)




OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
(7 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2000:699780 CAPLUS <>LOGINID::20091110>>  
DOCUMENT NUMBER: 134:52473  
TITLE: Syntheses and Properties of 1-Methyl-3-phenylaminobenzimidazolium Salts. Models of DNA Adducts of N7-Arylaminonitroxyguanine Nium Salt  
AUTHOR(S): Kaiya, Toyo; Fujiwara, Tomoko; Kohdo, Kohfuku  
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Nagoya City University, Mizuho-ku, Nagoya, 467-8603, Japan  
SOURCE: Chemical Research in Toxicology (2000), 13(10), 993-1001  
CODEN: CRTOEC; ISSN: 0893-228X  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 313486-00-9P  
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(Preparation and methylation)  
RN: 313486-00-9 CAPLUS  
CN: 1H-Benzimidazol-1-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



IT 313486-01-0P  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(Preparation of)  
RN: 313486-01-0 CAPLUS  
CN: 1H-Benzimidazolium, 1-methyl-5-nitro-3-(phenylamino)-, iodide (1:1) (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)  
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999-511140 CAPLUS <>LOGINID::20091110>>  
DOCUMENT NUMBER: 131:157771  
TITLE: Preparation of five-membered, benzo-condensed heterocycles as antithrombotics  
INVENTOR(S): Ries, Uwe; Hauel, Norbert; Mihm, Gerhard; Priepke, Henning; Binder, Klaus; Stassen, Jean Marie; Wiener, Wolfgang; Zimmermann, Rainer  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany  
SOURCE: PCT Int. Appl., 250 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:


| PATENT NO.  | KIND | DATE        | APPLICATION NO.  | DATE        |
|---|------|-------------|------------------|-------------|
| WO 9940072  | A1   | 19990812    | WO 1999-EP537    | 19990129 << |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UK, UG, VN, YU, ZW |      |             |                  |             |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BE, BJ, CF, CG, CI, GA, GN, GW, ML, MR, NE, SN, TD, TG  |      |             |                  |             |
| DE 19804085   | A1   | 19990805    | DE 1998-19804085 | 19980203 << |
| DE 19834325   | A1   | 23002017    | DE 1998-19834325 | 19980730 << |
| CA 2319434  | A1   | 19990812    | CA 1995-2319434  | 19990128 << |
| AU 9927201  | A    | 19990823    | AU 1995-27201    | 19990128 << |
| EP 1060168  | A1   | 200001220   | EP 1999-907437   | 19990128 << |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO   |      |             |                  |             |
| JP 200250284  | T    | 20020129    | JP 2000-530502   | 19990128 << |
| MX 20000505785  | A    | 23010123    | MX 2000-5785     | 20000612 << |
| PRIORITY AFFLN. INFO.:  |      |             |                  |             |
| DE 1998-19804085  | A    | 19980203 << |                  |             |
| DE 1998-19834325  | A    | 19980730 << |                  |             |
| WO 1999-EP537   | W    | 19990128 << |                  |             |

OTHER SOURCE(S): MARPAT 131:157771  
IT 236416-21-OP 236416-22-1P 236416-27-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of five-membered benzo-condensed heterocycles as antithrombotics)  
RN 236416-21-0 CAPLUS  
CN Glycine-N-(2-[(4-(Aminomethyl)phenyl]amino)-1-methyl-1H-benzimidazol-5-yl)-N-(3-quinolinylsulfonyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 236416-22-1 CAPLUS  
CN Glycine, N-[2-[(4-(aminoiminomethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, monohydrochloride (9Cl) (CA INDEX NAME)



● HCl


RN 236416-27-6 CAPLUS  
CN Benzeneacboximidamide, 4-[(1-methyl-5-[(8-quinolinylsulfonyl)amino]-1H-benzimidazol-2-yl)amino]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

IT 236417-44-0P 236417-45-1P 236417-46-2P  
236417-47-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)  
(preparation of five-membered benzo-condensed heterocycles as  
multichromophoric)  
RN 236417-44-0 CAPLUS  
CN Benzonitrile, 4-[(1-methyl-5-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-45-1 CAPLUS  
CN Benzonitrile, 4-[(5-amino-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)



RN 236417-46-2 CAPLUS  
CN 8-Quinolinesulfonamide, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 236417-47-3 CAPLUS  
CN Glycine, N-(2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)-N-(8-quinolinylsulfonyl)-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)  
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 17 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:505930 CAPLUS <<LOGINID::20091110>>  
 DOCUMENT NUMBER: 131:157761  
 TITLE: 5-Membered heterocyclic condensed benzoo derivatives,  
 their preparation and their use as drugs  
 INVENTOR(S): Ries, Uwe; Haubl, Norbert; Mihm, Gerhard; Priecke,  
 Henning; Binder, Klaus; Stasson, Jean Marie; Winnon,  
 Wolfgang; Zimmermann, Rainer  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany  
 SOURCE: Ger. Ofiz., 94 pp.  
 CODEN: GWXX5X  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| FATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE           |
|---|------|----------|------------------|----------------|
| DE 19804085   | A1   | 19930805 | DE 1988-19804085 | 19980203 <--   |
| CA 2119474  | A1   | 19990812 | CA 1999-2017494  | 19990128 <--   |
| WO 9940072  | A1   | 19990812 | WO 1999-EP537    | 19990128 <--   |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CL, CO, DE,<br>DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,<br>KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,<br>MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,<br>TR, TT, UA, UG, UZ, VN, YU, ZW |      |          |                  |                |
| RU: GH, GM, KE, LS, MN, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,<br>FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,<br>CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  |      |          |                  |                |
| AU 9927201  | A    | 19930823 | AU 1999-27201    | 19990128 <--   |
| EP 1060166  | A1   | 20001220 | EP 1999-907437   | 19990128 <--   |
| R: AT, BE, CH, DE, DK, ES, FR, GR, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO  |      |          |                  |                |
| JP 2002502844   | T    | 20020129 | JP 2000-510502   | 19980128 <--   |
| US 6114532  | A    | 20000905 | US 1999-243200   | 19990202 <--   |
| WO 200005785  | A    | 20010123 | WO 2000-5785     | 20000212 <--   |
| PRIORITY APPLN. INFO.:  |      |          | DE 1998-19804085 | A 19980203 <-- |
|   |      |          | US 1998-77694P   | P 19980312 <-- |
|   |      |          | DE 1998-19834325 | A 19980730 <-- |
|   |      |          | WO 1999-EP537    | W 19990128 <-- |

OTHER SOURCE(S): MARPAT 131:157761  
 IT 236416-21-OP 236417-44-OP 236417-45-1P  
 236417-46-2P 236417-47-3P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)  
 (preparation and antithrombotic activity of  
 benzoo-diazolylmethylbenzimidines)

RN 236416-21-OP CAPLUS  
 CN Glycine, N-(2-[(4-(aminoiminomethyl)phenyl]amino)-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 236417-44-0 CAPLUS  
 CN Benzonitrile, 4-[(1-methyl-5-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-45-1 CAPLUS  
 CN Benzonitrile, 4-[(5-amino-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-46-2 CAPLUS  
 CN 8-Quinolinesulfonamide, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 236417-47-3 CAPLUS  
 CN Glycine, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, ethyl ester (CA INDEX NAME)



IT 236416-22-1P 237750-43-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and antithrombotic activity of  
 benzimidazolylmethylbenzamidines)  
 RN 236416-22-1 CAPLUS  
 CN Glycine, N-[2-[(4-aminoiminomethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 237750-43-5 CAPLUS  
 CN Benzeneacboximidamide, 4-[(1-methyl-5-[(8-quinolinylsulfonyl)amino]-1H-benzimidazol-2-yl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

15 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 1998-906527 CAPLUS <>LOGIND::20091110>>  
 130:81512  
 DOCUMENT NUMBER:  
 TITLE: Preparation of benzoxazole, benzimidazole, and  
 benzothiazole compounds inhibiting production of  
 cytokine in type-2 helper T cell  
 INVENTOR(S): Tokunaga, Teruhisa; Fujita, Kazushi; Nagata, Ryu;  
 Ochi, Hiromi; Watanabe, Takamasa; Nakatani, Tomosuke  
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan; Sumitomo  
 Chemical Co., Ltd.  
 SOURCE: Jpn. Kokai Tokyo Koho, 336 pp.  
 CODEN: JKXXAF

DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE             | APPLICATION NO. | DATE          |
|---|------|------------------|-----------------|---------------|
| JP 10330369   | A    | 19981215         | JP 1997-225679  | 19970806 <<   |
| PRIORITY APPLN. INFO.:  |      |                  | JP 1997-102481  | A 19970404 << |
| OTHER SOURCE(S):  |      | MARPAT 130:81512 |                 |               |
| IT 218621-62-6P<br>RL: BAC (Biological activity or effector, except adverse); BSU (Biological<br>study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);<br>BIOL (Biological study); PREP (Preparation); USES (Uses)<br>(preparation of benzoxazole, benzimidazole, and benzothiazole compds.<br>inhibiting production of cytokine in type-2 helper T (Th2) cell for<br>treatment diseases related to hyperfunction of Th2 cells) |      |                  |                 |               |

RN 218621-62-6 CAPLUS  
 CN Phenol, 5-nitro-2-[(6-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

LS ANSWER 19 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1992-51052 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 117-111052

ORIGINAL REFERENCE NO.: 117-19359a, 19362a

TITLE: EPR study of nitroxyl radicals of substituted 5-anilinotriazoles, 5-anilinotetrazoles, and 2-anilinobenzimidazoles

AUTHOR(S): Omeika, Ladislav; Moska, Michael; Cholval, Vladimir; Svetlik, Jan; Schulz, Manfred

CORPORATE SOURCE: Dep. Phys. Chem., Slovak Tech. Univ., Bratislava, 812 37, Czech.

SOURCE: Collection of Czechoslovak Chemical Communications (1992), 57(5), 1065-71

DOCUMENT TYPE: CODEN: CCCCAK; ISSN: 0010-0765

LANGUAGE: Journal


IT 143017-91-8 143017-92-9

RL: FRP (Properties)


(ESR of)

RN 143017-91-8 CAPLUS

CN Nitroxide, 5-nitro-1H-benzimidazol-2-yl phenyl (9CI) (CA INDEX NAME)




RN 143017-92-9 CAPLUS  
CN Nitroxide, 4-Methoxyphenyl 5-nitro-1H-benzimidazol-2-yl (9CI) (CA INDEX NAME)




IT 86601-34-5 86601-36-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(oxidation of, with peroxy radical, nitroxide from)

RN 86601-34-5 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



RN 86601-36-7 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-6-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)

LS ANSWER 20 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1991-449687 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 115-49687

ORIGINAL REFERENCE NO.: 115-86334, 86364

TITLE: Preparation of aminobenzimidazoles as dual inhibitors of lipoxygenase and cyclooxygenase enzymes

INVENTOR(S): Steven, Rodney W.; Maesani, Nakane

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: Eur. Pat. Appl., 19 pp.

DOCUMENT TYPE: CODEN: EPXXDW

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE          |
|---|------|----------|-----------------|---------------|
| EP 419210   | A1   | 19910327 | EP 1990-310199  | 19900918 <<   |
| EP 419210   | B1   | 19911102 |                 |               |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE |      |          |                 |               |
| JP 06009378   | A    | 19910509 | JP 1989-246732  | 19890922 <<   |
| JP 06009378   | B    | 19940105 |                 |               |
| US 5141950  | A    | 19920825 | US 1990-583264  | 19900914 <<   |
| AT 113586   | T    | 19941115 | AT 1990-310199  | 19900918 <<   |
| ES 2062395  | T3   | 19941216 | ES 1990-310199  | 19900918 <<   |
| CA 2025849  | A1   | 19910123 | CA 1990-2025849 | 19900925 <<   |
| PRIORITY APPLN. INFO.:                                    |      |          | JP 1989-246732  | A 19890922 << |

OTHER SOURCE(S): MARPAT 115:49687

IT 134869-16-2P 134869-17-3P 134869-18-4P

134869-19-5P 134869-20-8P 134869-21-9P


134869-22-0P 134869-25-3P 134869-26-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as lipoxygenase and cyclooxygenase inhibitor)


RN 134869-16-2 CAPLUS

CN 1H-Benzimidazole-2,6-diamino, N2-phenyl-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-17-3 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(3-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-18-4 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-19-5 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-20-8 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-butylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-21-9 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(1-naphthalenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●3 HCl

RN 134869-22-0 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N6-(phenylmethyl)-N2-(3-pyridinyl)-, hydrochloride (1:3) (CA INDEX NAME)




●2 HCl

RN 134869-25-3 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(3-methoxyphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-26-4 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-methyl-N2-phenyl-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

IT 134869-39-9  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reductive benzylation of, by benzaldehyde)  
RN 134869-39-9 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)

LS ANSWER 21 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 114:81830 CAPLUS <<LOGINID::20091110>>  
DOCUMENT NUMBER: 114:81830  
ORIGINAL REFERENCE NO.: 114:139764,139773  
TITLE: Preparation of benzimidazole derivatives and analogs as antiulcer and cardiovascular agents  
INVENTOR(S): Bru-Magniez, Nicole; Gungor, Timur; Lacrampe, Jean; Launay, Michele; Teulon, Jean Marie  
PATENT ASSIGNEE(S): Laboratoires U.P.S.A., Fr.  
SOURCE: Eur. Pat. Appl., 70 pp.  
CODEN: EPXXDW


DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.   | KIND                                 | DATE     | APPLICATION NO. | DATE           |
|--|--------------------------------------|----------|-----------------|----------------|
| EP 385850  | A2                                   | 19900905 | EP 1990-400537  | 19900227 <--   |
| EP 385850  | A3                                   | 19901219 |                 |                |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE  |                                      |          |                 |                |
| FR 2643903   | A1                                   | 19900907 | FR 1989-2833    | 19890303 <--   |
| CA 2011222   | A1                                   | 19900903 | CA 1990-2011222 | 19900301 <--   |
| AU 9050611   | A                                    | 19900906 | AU 1990-50611   | 19900302 <--   |
| ZA 9001602   | A                                    | 19901228 | ZA 1990-1602    | 19900302 <--   |
| JP 03014579  | A                                    | 19901023 | JP 1990-52567   | 19900303 <--   |
| PRIORITY APPLN. INFO.:   |                                      |          | FR 1989-2833    | A 19890303 <-- |
| OTHER SOURCE(S):   | CASREACT 114:81830; MARPAT 114:81830 |          |                 |                |
| IT 111884-91-8P  |                                      |          |                 |                |
| RL: SPN (Synthetic preparation); PREP (Preparation)<br>(preparation of, as antiulcer and cardiovascular agent) |                                      |          |                 |                |
| RN 131884-91-8 CAPLUS  |                                      |          |                 |                |
| CN 1H-Benzimidazol-2-amine, 6-(1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)                                |                                      |          |                 |                |




OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

LS ANSWER 22 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 113:78244 CAPLUS <<LOGINID::20091110>>  
DOCUMENT NUMBER: 113:78244  
ORIGINAL REFERENCE NO.: 113:13238,13242  
TITLE: Diheterocyclic compounds from dithiocarbamates and derivatives thereof. I, 2,2'-(Arylenediaminobis)benzozoles, 2,2'-(Arylenediaminobis)imidazopyridines and 8,8'-(Arylenediaminobis)spurines  
AUTHOR(S): Garin, Javier; Melendez, Enrique; Merchan, Francisco L.; Merino, Pedro; Orduna, Jesus; Tejedor, Rosa; Tejero, Tomas  
CORPORATE SOURCE: Inst. Cienc. Mater. Aragon, Univ. Zaragoza, Zaragoza, E-50009, Spain  
SOURCE: Journal of Heterocyclic Chemistry (1990), 27(2), 221-6  
DOCUMENT TYPE: CODEN: JHTCAD; ISSN: 0022-152X  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 113:78244  
IT 128587-22-4P 128587-27-9P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 128587-22-4 CAPLUS  
CN 1,4-Benzenediamine, N1,N4-bis(6-nitro-1H-benzimidazol-2-yl)- (CA INDEX NAME)




RN 128587-27-9 CAPLUS  
 CN 1,4-Benzene-diamine, 2-methyl-N1,N4-bis(6-nitro-1H-benzimidazol-2-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
 (3 CITINGS)

15 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1988:632046 CAPLUS <<LOGINID:20091110>>  
 DOCUMENT NUMBER: 109:232046  
 ORIGINAL REFERENCE NO.: 109:38399a,38402a  
 TITLE: Antioxidative efficiency of substituted N-phenyl  
 N-pyrazolyl-3, N-phenyl N-benzimidazolyl-2, and  
 N-benzimidazolyl-2 N-benzimidazolyl-2 amines in the  
 thermooxidation of polypropylene  
 AUTHOR(S): Matyssova-Rychly, L.; Rychly, J.; Menke, M.; Schulz, M.  
 CORPORATE SOURCE: Cent. Chem. Res., Slovak Acad. Sci., Bratislava, 842  
 36, Czechoslovakia  
 SOURCE: Polymer Degradation and Stability (1998),  
 21(4), 323-33  
 CODEN: PDSTDW; ISSN: 0141-3910  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 86601-36-7  
 RL: USES (Uses)  
 (antioxidative efficiency of, in thermooxidn. of isotactic  
 polypropylene)  
 RN 86601-36-7 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-6-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)


15 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1983:539933 CAPLUS <<LOGINID:20091110>>  
 DOCUMENT NUMBER: 99:139933  
 ORIGINAL REFERENCE NO.: 99:21501a,21504a  
 TITLE: Heterocyclic diarylamine derivatives  
 INVENTOR(S): Serban, Alexander; Watson, Keith G.; Barton, John E.  
 D.  
 PATENT ASSIGNEE(S): ICI Australia Ltd., Australia  
 SOURCE: Can., 69 pp.  
 CODEN: CAXXA4  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE     | APPLICATION NO. | DATE         |
|------------|------|----------|-----------------|--------------|
| CA 1145344 | A1   | 19830426 | CA 1980-347768  | 19800317 <-- |
| AU 8055985 | A    | 19800925 | AU 1980-55985   | 19790319 <-- |
| AU 5340493 | B2   | 19840105 |                 |              |
| ZA 8001246 | A    | 19810325 | ZA 1980-1246    | 19800304 <-- |
| HU 75187   | A2   | 19830628 | HU 1980-603     | 19800314 <-- |
| HU 183116  | B    | 19840228 |                 |              |

PRIORITY APPN. INFO.: AD 1979-8094 A 19790319 <--  
 GB 1979-10365 A 19790412 <--  
 AU 1979-8886 A 19790522 <--


IT 77206-07-6P  
 RL: PAC (Biological activity or effector, except adverse); BSL (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and herbicidal activity of)

RN 77206-07-6 CAPLUS  
 CN Propionic acid, 2-[4-(methyl(6-nitro-1H-benzimidazol-2-yl)amino)phenoxy]-, methyl ester (CA INDEX NAME)




15 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1983:470625 CAPLUS <<LOGINID:20091110>>  
 DOCUMENT NUMBER: 99:10970a  
 ORIGINAL REFERENCE NO.: 99:1097a,10970a  
 TITLE: A facile synthesis of dimethyl  
 N-acylidithiocarbonimidates and  
 Z-aryliminobenzimidazoles  
 AUTHOR(S): Garin, J.; Melendez, E.; Merchan, F. L.; Tejel, C.;  
 Tejero, T.  
 CORPORATE SOURCE: Dep. Quim. Org., Univ. Zaragoza, Zaragoza, Spain  
 SOURCE: Synthesis (1983), (5), 375-6  
 CODEN: SYNTDF; ISSN: 0039-7881


DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 86601-34-5P 86601-35-6P 86601-36-7P  
 86601-37-8P  
 KL: SNN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 86601-34-5 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)




RN 86601-35-6 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-methylphenyl)-6-nitro- (CA INDEX NAME)



RN 86601-36-7 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-6-nitro- (CA INDEX NAME)



RN 86601-37-8 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(3-chloro-2-methylphenyl)-6-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
 (6 CITINGS)

L5 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1981:156918 CAPLUS <<LOGINID:20091110>>  
 DOCUMENT NUMBER: 94:156918

ORIGINAL REFERENCE NO.: 94:25657a,25660a  
 TITLE: Herbicidal diarylamine derivatives  
 INVENTOR(S): Barton, John Edward Duncan; Serban, Alexander; Watson, Keith Geoffrey  
 PATENT ASSIGNEE(S): ICI Australia Ltd., Australia  
 SOURCE: Eur. Pat. Appl., 75 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


| PATENT NO.                    | KIND | DATE     | APPLICATION NO. | DATE         |
|-------------------------------|------|----------|-----------------|--------------|
| EP 180082                     | A1   | 19800129 | EP 1980-300793  | 19800314 <-- |
| EP 180083                     | B1   | 19800404 |                 |              |
| R: BE, CH, DE, FR, GB, IT, NL |      |          |                 |              |
| AU 655985                     | A    | 19800325 | AU 1980-55985   | 19790319 <-- |
| AU 534093                     | Z2   | 19840105 |                 |              |
| ZA 8001246                    | A    | 19810328 | ZA 1980-1246    | 19800304 <-- |
| IL 59533                      | A    | 19850131 | IL 1980-59533   | 19800305 <-- |
| HU 25187                      | A2   | 19830628 | HU 1980-603     | 19800314 <-- |
| HU 183116                     | B    | 19840428 |                 |              |
| US 4314065                    | A    | 19820202 | US 1980-131389  | 19800317 <-- |
| BR 8001616                    | A    | 19800118 | BR 1980-1618    | 19800318 <-- |
| JP 55149263                   | A    | 19800120 | JP 1980-33480   | 19800318 <-- |
| JP 04028701                   | B    | 19920515 |                 |              |

| PRIORITY APPLN. INFO.: | AU 1979-8094  | A 19790319 <-- |
|------------------------|---------------|----------------|
|                        | GB 1979-13065 | A 19790412 <-- |
|                        | AU 1979-8866  | A 19790522 <-- |

OTHER SOURCE(S): CASREACT 94:156918

IT 77205-07-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, not specified); SPP (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and herbicidal activity of)

RN 77205-07-6 CAPLUS  
 CN Propanoic acid, 2-(4-(methyl(6-nitro-1H-benzimidazol-2-yl)amino)phenoxy)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD  
 (4 CITINGS)


L5 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1973:58423 CAPLUS <<LOGINID:20091110>>  
 DOCUMENT NUMBER: 78:58423  
 ORIGINAL REFERENCE NO.: 78:9271a,9274a  
 TITLE: Anthelmintic isothiocyanatobenzothiazoles, -benzimidazoles, and -benzoxazoles  
 INVENTOR(S): Brenneisen, Paul; Wenger, Thomas; Galley, Jean Jacques; Schmid, Wolfgang  
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G.

SOURCE: Ger. Offen., 46 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE            |
|------------------------|------|----------|-----------------|-----------------|
| DE 2225071             | A    | 19721207 | DE 1972-2225071 | 19720523 <--    |
| US 3840550             | A    | 19741008 | US 1972-255334  | 19720522 <--    |
| BE 783791              | A1   | 19721123 | BE 1972-117737  | 19720523 <--    |
| NL 7206929             | A    | 19721120 | NL 1972-6929    | 19720523 <--    |
| FR 2138884             | A1   | 19730105 | FR 1972-18265   | 19720523 <--    |
| ZA 7203514             | A    | 19730328 | ZA 1972-3514    | 19720523 <--    |
| DD 98517               | A5   | 19730620 | DD 1972-163138  | 19720523 <--    |
| US 3894037             | A    | 19750708 | US 1974-491585  | 19740724 <--    |
| US 3933841             | A    | 19760120 | US 1974-491584  | 19740724 <--    |
| PRIORITY APPLN. INFO.: |      |          | CH 1971-7542    | A 19710524 <--  |
|                        |      |          | US 1972-255334  | A3 19720522 <-- |
|                        |      |          | US 1974-255334  | A3 19740522 <-- |

IT 39223-75-1P 39480-77-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 39223-75-1 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 6-isothiocyanato-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 39480-77-8 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-chlorophenyl)-6-isothiocyanato-, hydrochloride (1:1) (CA INDEX NAME)




• HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)


L5 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1964:418220 CAPLUS <<LOGINID:20091110>>  
 DOCUMENT NUMBER: 61:18220  
 ORIGINAL REFERENCE NO.: 61:3091d-t

TITLE: Carbonimidoyl dihalides as organic intermediates. I.  
 The preparation of 2-arylaminobenzimidazoles  
 AUTHOR(S): Murphy, Daniel B.  
 CORPORATE SOURCE: City Univ. of New York, New York, NY  
 SOURCE: Journal of Organic Chemistry (1964), 29(6), 1613-15  
 CODEN: JOCEAH; ISSN: 0022-3263


DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 OTHER SOURCE(S): CASREACT 61:18220  
 IT 86601-34-5P, Benzimidazole, 2-anilino-5(or 6)-nitro-  
 97027-41-3P, Benzimidazole, 2-anilino-5-chloro-7-nitro-(?)  
 97028-28-9P, Benzimidazole,  
 6-chloro-2-(p-chloroanilino)-4-nitro-(?)  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 86601-34-5 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



RN 97027-41-3 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 5-chloro-7-nitro-N-phenyl- (CA INDEX NAME)



RN 97028-28-9 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 5-chloro-N-(4-chlorophenyl)-7-nitro- (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD  
 (4 CITINGS)


L5 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1962:13033 CAPLUS  
 DOCUMENT NUMBER: 56:13033  
 ORIGINAL REFERENCE NO.: 56:2457a-b

TITLE: Compounds containing both cyclic amidine and alkylene rings  
 INVENTOR(S): Shan, Kwan Ting  
 PATENT ASSIGNEE(S): Petroline Corp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE  
 US 2987522 D1 19610805 US 1958-721643 19580317 <--  
 IT 96170-15-9 96971-20-9 98422-81-2  
 100628-77-1 101320-03-0 102345-66-4  
 107541-46-8  
 (Derived from data in the 7th Collective Formula Index (1962-1966))  
 RN 96170-15-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro- (CA INDEX NAME)




RN 96971-20-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)(phenylmethyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:2) (CA INDEX NAME)



RN 98422-81-2 CAPLUS  
 CN Glycine, N-[1-(2-(diethylamino)ethyl)-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester (7CI) (CA INDEX NAME)




RN 100628-77-1 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 101320-03-0 CAPLUS  
 CN 2-Benzimidazolecarboxylic acid, 1-[2-(diethylamino)ethyl]-N-(p-ethoxyphenyl)-5-nitro-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)




● x HCl

RN 102345-66-4 CAPLUS  
 CN Benzamide, N-[1-(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 107541-46-8 CAPLUS  
Glycine, N-[1-(2-(diethylamino)ethyl)-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride (7Cl) (CA INDEX NAME)




● HCl

IT 101548-62-3P, p-Propionophenetidide,  
N-[1-(2-(diethylamino)ethyl)-5-nitro-2-benzimidazolyl]-  
101548-63-4P, p-Propionophenetidide,  
N-[1-(2-(diethylamino)ethyl)-5-nitro-2-benzimidazolyl]-, hydrochloride  
RL: FRP (Preparation)  
(Preparation of)  
RN 101548-62-3 CANUS  
CN Propanamide, N-[1-(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)



RN 101548-63-4 CAPLUS  
CN Propanamide, N-[1-(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)


45 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1962-13032 CAPLUS  
DOCUMENT NUMBER: 56-13032  
ORIGINAL REFERENCE NO.: 56-24551, 2456a-i, 2457a  
TITLE: Benzimidazoles  
INVENTOR(S): Hoffmann, Karl; Hungar, Alfred; Kehrl, Jindrich;  
Rossi, Alberto  
PATENT ASSIGNEE(S): Ciba Pharmaceutical Products, Inc.  
DOCUMENT TYPE: Patent  
LANGUAGE: Unavailable  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.   | KIND | DATE         | APPLICATION NO. | DATE         |
|--|------|--------------|-----------------|--------------|
| US 3000898   | US   | 19580919     | US              | <--          |
| GB 229254  | GB   |              | GB              |              |
|  |      |              | CH              | 19590831 <-- |
| PRIORITY APPLICATION INFO.:  |      |              |                 |              |
| IT 94916-17-3P, Benzimidazole,<br>2-anilino-1-(2-(diethylamino)ethyl)-5-nitro-   |      | 94916-20-8P, |                 |              |
| Benzimidazole, 1-(2-(dimethylamino)ethyl)-5-nitro-2-p-phenetidino-   |      |              |                 |              |
| 95128-90-8P, Benzimidazole,<br>1-(2-(diethylamino)ethyl)-2-[N-(p-methoxyphenyl)acetamido]-5-nitro-   |      |              |                 |              |
| 95698-89-8P, Benzimidazole,<br>2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-1-(2-piperidinoethyl)-  |      |              |                 |              |
| 96167-31-6P, Benzimidazole,<br>1-(2-(dimethylamino)ethyl)-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-   |      |              |                 |              |
| 96167-54-3P, Benzimidazole,<br>1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidino-  |      | 96170-15-9P  |                 |              |
| , Benzimidazole, 1-(2-(diethylamino)ethyl)-2-(N-ethyl-p-phenetidino)-5-  |      |              |                 |              |
| nitro- 96309-87-4P, Benzimidazole,<br>1-[2-(diethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-   |      |              |                 |              |
| 96310-20-5P, Benzimidazole,<br>2-(N-benzyl-p-phenetidino)-1-[2-(diethylamino)ethyl]-5-nitro-,<br>dihydrochloride 97297-44-4P, Benzimidazole,<br>5-nitro-2-p-phenetidino-1-(2-piperidinoethyl)- 97297-45-5P,  |      |              |                 |              |
| Propionanilide, N-[1-(2-(diethylamino)ethyl)-5-nitro-2-benzimidazolyl]-<br>98422-81-2P, Glycine, N-[1-(2-(diethylamino)ethyl)-5-nitro-2-   |      |              |                 |              |
| benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester 100176-34-9P,<br>Benzimidazole, 1-[2-(dimethylamino)ethyl]-5-nitro-2-p-phenetidino-,<br>hydrochloride 100260-95-5P, Benzimidazole,<br>2-anilino-1-(2-(diethylamino)ethyl)-5-nitro-, hydrochloride |      |              |                 |              |


100433-67-8P, Benzimidazole,  
 1-[2-(diethylaminoethyl)-5-nitro-2-(N-phenylacetamido)-, hydrochloride  
 100628-46-4P, Benzimidazole,  
 1-[2-(diethylaminoethyl)-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-,  
 hydrochloride 100628-59-9P, Benzimidazole,  
 1-[2-(diethylaminoethyl)-5-nitro-2-p-phenetidino-, hydrochloride  
 100628-71-2P, Benzimidazole,  
 1-[2-(diethylaminoethyl)-2-(N-ethyl-p-phenetidino)-5-nitro-,  
 hydrochloride 101016-59-5P, Benzimidazole,  
 1-[2-(diethylaminoethyl)-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-,  
 hydrochloride 101320-03-0P, 2-Benzimidazolescarbamic acid,  
 1-[2-(diethylaminoethyl)-N-(p-ethoxyphenyl)-5-nitro, ethyl ester,  
 hydrochloride 101548-62-3P, p-Propionophenetidide,  
 N-1-[2-(diethylaminoethyl)-5-nitro-2-benzimidazolyl]-  
 101548-63-4P, p-Propionophenetidide,  
 N-1-[2-(diethylaminoethyl)-5-nitro-2-benzimidazolyl]-, hydrochloride  
 102345-66-4P, Benzimidazole,  
 1-[2-(diethylaminoethyl)-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-,  
 hydrochloride 104352-29-6P, Benzimidazole,  
 1-[2-(diethylaminoethyl)-2-(N-(p-ethoxyphenyl)acetamido)-5-nitro-,  
 hydrochloride 104763-43-1P, p-Formophenetidide,  
 N-1-[2-(diethylaminoethyl)-5-nitro-2-benzimidazolyl]-  
 104763-48-2P, p-Formophenetidide,  
 N-1-[2-(diethylaminoethyl)-5-nitro-2-benzimidazolyl]-, hydrochloride  
 104763-51-1P, Propionanilide,  
 N-1-[2-(diethylaminoethyl)-5-nitro-2-benzimidazolyl]-, hydrochloride  
 104763-77-1P, Benzimidazole,  
 5-nitro-2-p-phenetidino-1-(2-piperidinomethyl)-, hydrochloride  
 107541-46-8P, Glycine, N-1-[2-(diethylaminoethyl)-5-nitro-2-  
 benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride  
 875932-28-3P, Benzimidazole,  
 2-p-anisidino-1-[2-(diethylaminoethyl)-5-nitro- 875932-71-4P,  
 Benzimidazole, 2-p-anisidino-1-[2-(diethylaminoethyl)-5-nitro-,  
 hydrochloride  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 94916-17-3 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)- (CA  
 INDEX NAME)





RN 94916-20-8 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-  
 nitro- (CA INDEX NAME)




RN 95128-90-8 CAPLUS  
 CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-  
 methoxyphenyl)- (CA INDEX NAME)




RN 95698-89-8 CAPLUS  
 CN Acetamide, N-(4-ethoxyphenyl)-N-[5-nitro-1-[2-(1-piperidinyl)ethyl]-1H-  
 benzimidazol-2-yl]- (CA INDEX NAME)




RN 96167-31-6 CAPLUS  
 CN Acetamide, N-[1-[2-(dimethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 96167-54-3 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-  
 nitro- (CA INDEX NAME)




RN 96170-15-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-  
 5-nitro- (CA INDEX NAME)



RN 96309-07-4 CAPLUS  
 CN Acetamide, N-[1-[(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 96371-20-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)(phenylmethyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 97297-44-4 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 97297-45-5 CAPLUS  
 CN Propanamide, N-1-[(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-phenyl- (CA INDEX NAME)



RN 98422-81-2 CAPLUS  
 CN Glycine, N-[1-[(2-(diethylamino)ethyl)-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester (7CI) (CA INDEX NAME)




RN 100176-34-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 100260-95-5 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 100433-67-8 CAPLUS  
CN Acetamide, N-[1-(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-phenyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 100628-45-4 CAPLUS  
CN Acetamide, N-[1-(2-(dimethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 100628-59-9 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 100628-77-1 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethoxyamino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 101016-59-5 CAPLUS  
CN Acetamide, N-[1-(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 101320-03-0 CAPLUS  
CN 2-Benzimidazolecarboxylic acid, 1-(2-(diethylamino)ethyl)-N-(p-ethoxyphenyl)-5-nitro-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)




● x HCl

RN 101548-62-3 CAPLUS  
CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 101548-63-4 CAPLUS  
CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 102345-66-4 CAPLUS  
CN Benzamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 104352-29-6 CAPLUS  
CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 104763-43-1 CAPLUS  
CN Formamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 104763-44-2 CAPLUS  
CN Formamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)





● HCl

RN 104763-51-1 CAPLUS  
CN Propanamide, N-[1-(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-phenyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 104763-77-1 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-(2-(1-piperidinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 107541-46-8 CAPLUS  
CN Glycine, N-[1-(2-(diethylamino)ethyl)-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)




● HCl

RN 875832-28-3 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)



RN 879654-71-4 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L5 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1962:12986 CAPLUS <<LOGINID:20091110>>  
DOCUMENT NUMBER: 56:12986  
ORIGINAL REFERENCE NO.: 56:2437g-i  
TITLE: N-Acetylated pyrazolones  
AUTHOR(S): Wahlberg, Erik  
CORPORATE SOURCE: Univ. Uppsala, Swed.  
SOURCE: Arkiv voor Kemi (1960), 17, 83-8  
CODEN: ARKEAD; ISSN: 0365-6128


DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 IT 94916-20-8 96167-54-3 97297-44-4  
 100176-34-9 100628-59-9 104763-77-1  
 (Derived from data in the 7th Collective Formula Index (1962-1966))  
 RN 94916-20-8 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro- (CA INDEX NAME)




RN 96167-54-3 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro- (CA INDEX NAME)




RN 97297-44-4 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 100176-34-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



RN 100628-59-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



RN 104763-77-1 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



15 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1962:12985 CAPLUS <<LOGINID::20091110>>  
 DOCUMENT NUMBER: 56:12985  
 ORIGINAL REFERENCE NO.: 56:2436h-1,2437a-g

TITLE: Benzimidazole and related heterocycles. VII. New 2-aminobenzimidazoles  
 AUTHOR(S): Hunger, A.; Kebrie, J.; Rossi, A.; Hoffmann, K.  
 CORPORATE SOURCE: CIBA A.-G., Basel, Switz.  
 SOURCE: Helvetica Chimica Acta (1961), 44, 1273-82  
 CODEN: HCACAV; ISSN: 0018-019X

DOCUMENT TYPE: Document

LANGUAGE: German


OTHER SOURCE(S): CASREACT 56:12985

IT 94916-17-3P, Benzimidazole, 2-anilino-1-[2-(diethylaminoethyl)-5-nitro-, 94916-20-8P, Benzimidazole, 1-(2-(dimethylamino)ethyl)-5-nitro-2-p-phenetidino-96167-54-1P, Benzimidazole, 1-(2-(diethylaminoethyl)-5-nitro-2-p-phenetidino-, 97297-44-4P, Benzimidazole, 5-nitro-2-p-phenetidino-1-(2-piperidinoethyl)-100176-34-9P, Benzimidazole, 1-(2-(dimethylaminoethyl)-5-nitro-2-p-phenetidino-, hydrochloride 100260-95-5P, Benzimidazole, 2-anilino-1-[2-(diethylaminoethyl)-5-nitro-, hydrochloride 100628-59-9P, Benzimidazole, 1-(2-(diethylaminoethyl)-5-nitro-2-p-phenetidino-, hydrochloride 104763-77-1P, Benzimidazole, 5-nitro-2-p-phenetidino-1-(2-piperidinoethyl)-, hydrochloride 875832-20-3P, Benzimidazole, 2-anilino-1-(2-(diethylaminoethyl)-5-nitro-, 879654-7)-4P, Benzimidazole, 2-p-anisidino-1-[2-(diethylaminoethyl)-5-nitro-, hydrochloride


RL: PREP (Preparation)  
 (preparation of)

RN 94916-17-3 CAPLUS


CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)- (CA INDEX NAME)





RN 94916-20-8 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro- (CA INDEX NAME)




RN 96167-54-3 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro- (CA INDEX NAME)



RN 97297-44-4 CAPLUS  
 CN 1H-Benzimidazole-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-(2-(1-piperidinyl)ethyl)- (CA INDEX NAME)




RN 100176-34-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 100260-95-5 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)-, hydrochloride (1:?) (CA INDEX NAME)





● x HCl

RN 100628-59-9 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 104763-77-1 CAPLUS  
CN 1H-Benzimidazole-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-(2-(1-piperidinylolethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● x HCl

RN 875032-20-3 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro- (CA INDEX NAME)




RN 879654-71-4 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● x HCl

US.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(5 CITINGS)

1.5 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACQUISITION NUMBER: 1933-51359 CAPLUS <<LOGINID::20091110>>  
DOCUMENT NUMBER: 47-51359  
ORIGINAL REFERENCE NO.: 47:86639-1, 8670a-e  
TITLE: Aromatic diazo compounds. VII. Coupling with  
m-phenylenediamine  
AUTHOR(S): Muzik, Ferdinand; Allan, Zdenek J.  
CORPORATE SOURCE: Chem. Research Inst., Pardubice-Rybitvi, Czech.  
SOURCE: Chemicke Listy pro Vedu a Prumysl (1952),  
27-80, 350-7  
CODEN: CLPRAN; ISSN: 0366-6832  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable  
IT 853788-72-4P, Benzimidazole,  
7-acetamido-1-p-chloranilino-4-(p-chlorophenylazo)-2,6-dimethyl-  
RL: PREP (Preparation)  
(preparation of)  
RN 853788-72-4 CAPLUS  
CN Acetamide, N-[(4-chlorophenyl)amino]-4-[2-(4-chlorophenyl)diazenyl]-2,6-  
dimethyl-1H-benzimidazol-7-yl]- (CA INDEX NAME)



LS ANSWER 34 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1951-43092 CAPLUS

DOCUMENT NUMBER: 45:43092

ORIGINAL REFERENCE NO.: 45:7360f-i, 7361a-b, 7362a

TITLE: Amino derivatives

INVENTOR(S): Ackermann, Franz

PATENT ASSIGNEE(S): C I B A Ltd.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND     | DATE          | APPLICATION NO. | DATE         |
|------------|----------|---------------|-----------------|--------------|
| US 2550321 | 19510424 | US 1948-60400 |                 | 19481116 <-- |

IT 855839-87-1P, Methanesulfonic acid, [(6-(methylamino)-2-benzimidazolyl)anilino]-


(RL: PREP (preparation)

(preparation of)

RN 855839-87-1 CAPLUS

CN Methanesulfonic acid, 1-[(6-(methylsulfoamino)-1H-benzimidazol-2-

yl)phenylamino]- (CA INDEX NAME)



LS ANSWER 35 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1924-12159 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 18:12159


ORIGINAL REFERENCE NO.: 18:1652d-1, 1653a-g

TITLE: Constitution of the reaction products from o-aminoazo


compounds and aldehydes. II  
 AUTHOR(S): Fincher, Otto  
 SOURCE: Journal für die Praktische Chemie (Leipzig) (1924)  
 ) 137, 16-49  
 CODEN: JPCZAO; ISSN: 0021-0383  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 IT 861781-92-8, Benzimidazole, 5-amino-1-anilino-2-phenyl-  
 (and derivs.)  
 RN 861783-92-8 CAPLUS  
 CN 1H-Benzimidazole-1,5-diamine, N1,2-diphenyl- (CA INDEX NAME)




IT 861293-79-0P, Benzimidazole,  
 1-(N-nitrosoanilino)-5-salicylalamino-2-salicyl- 861305-30-8P,  
 Benzimidazole, 1-anilino-5-salicylalamino-2-salicyl-  
 861305-32-0P, Benzimidazole, 1-anilino-5-benzalamino-2-phenyl-  
 861783-94-0P, Benzimidazole,  
 5-acetamido-1-(N-acetylaminino)-2-phenyl- 861800-49-9P,  
 Benzimidazole, 5-benzalamino-1-(N-nitrosoanilino)-2-phenyl-  
 RU: PREP (Preparation)  
 (preparation of)  
 RN 861293-79-0 CAPLUS  
 CN Phenol, 2-[(5-1[(2-hydroxyphenyl)methylene]amino)-1-(nitrosophenylamino)-  
 1H-benzimidazol-2-yl)methyl]- (CA INDEX NAME)




RN 861305-30-8 CAPLUS  
 CN Phenol, 2-[(5-1[(2-hydroxyphenyl)methylene]amino)-1-(phenylamino)-1H-  
 benzimidazol-2-yl)methyl]- (CA INDEX NAME)




RN 861305-32-0 CAPLUS  
CN 1H-Benzimidazole-1,5-diamine, N1,2-diphenyl-N5-(phenylmethylene)- (CA INDEX NAME)



RN 861783-94-0 CAPLUS  
CN Acetamide, N-[5-(acetylaminio)-2-phenyl-1H-benzimidazol-1-yl]-N-phenyl- (CA INDEX NAME)




RN 861800-49-9 CAPLUS  
CN 1H-Benzimidazole-1,5-diamine, N1-nitroso-N1,2-diphenyl-N5-(phenylmethylene)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

LS ANSWER 36 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1913:8050 CAPLUS <>LOGINID::20091110>>  
DOCUMENT NUMBER: 7:8050  
ORIGINAL REFERENCE NO.: 7:1184d-1,1185a-e  
TITLE: Substituted hydroxy- and  
o-Methylbenzimidazoles  
AUTHOR(S): Kym, E.; Retmer, L.  
CORPORATE SOURCE: Univ. Zurich  
SOURCE: Berichte der Deutschen Chemischen Gesellschaft (1913), 45, 3238-55  
CODEN: BDCCAS; ISSN: 0365-9496  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable  
IT 86601-34-5P, Benzimidazole, 2-anilino-5-nitro-

RL: PREP (Preparation)  
(preparation of)  
RN 86601-34-5 CAPLUS  
CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



=> File: stnguide  
FILE IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (>).

=> file stnguide  
COST IN U.S. DOLLARS  
SINCE FILE ENTRY TOTAL  
SESSION  
FULL ESTIMATED COST 150.76 337.34

FILE 'STNGUIDE' ENTERED AT 09:17:46 ON 10 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Nov. 6, 2009 (20091106/UP).

=> log  
ALL LOG QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y)/N/HOLD/Y

(FILE 'HOME' ENTERED AT 09:11:43 ON 10 NOV 2009)

FILE 'REGISTRY' ENTERED AT 09:11:53 ON 10 NOV 2009  
L1 STRUCTURE UPLOADED  
D  
L2 3 SEA FILE=REGISTRY SSS SAM LI  
L3 586 SEA FILE=REGISTRY SSS FUL LI

FILE 'CAPLUS' ENTERED AT 09:13:01 ON 10 NOV 2009  
L4 51 SEA FILE=CAPLUS SPC=ON ARB=ON FLD=ON L3  
L5 36 SEA FILE=CAPLUS SPC=ON ARB=ON FLD=ON L4 AND (PD<20041027 OR  
PRD<20041027 OR AD<20041027)  
D 1-36 1R1B HITSTR